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Abstract
Two non-transformed revertants of the HeLa (ATCC CCL2) cell line have been isolated
using a selection procedure based on prolonged retention of the fluorescent dye, rhodamine 123,
within the mitochondria of carcinoma cells versus normal epithelial cells. Unlike the parental
HeLa, the revertant cells exhibited a flat non-refractile morphology, failed to grow in suspension
culture, had more than 100-fold lower cloning efficiencies in semi-solid medium, and failed to
induce subcutaneous tumors when injected into nude mice. Both clones have retained a revertant
phenotype after more than three years of continuous culture.
Somatic cell fusion experiments suggested that revertant cells had sustained a mutation or
mutations that resulted in the activation of a dominant suppressor of transformation. Molecular
characterization of these revertants demonstrated that the HPV-18 sequences present in the
parental HeLa cells are retained in the revertants. Expression of the HPV-18 E6 and E7 at both
the mRNA and protein levels were comparable to those seen in the parental HeLa line, suggesting
that loss of the viral oncogenes was not responsible for loss of the tumorigenic phenotype in
either clone. Among other possibilities, it was reasoned that a change in a regulator of the HPV
oncoproteins or of the Rb and p53 genes could have interrupted the oncogene-suppressor
association and have thus led to an activation of either Rb or p53. Using immunoaffinity
purification and immunoblotting experiments no difference in Rb steady state levels were
observed but increased p53 protein levels were found in both revertants as compared to Hela.. It
is shown that functional activation of the p53 pathway is an obligatory step in the reversion
process. The HeLa cells express wild-type p53 whose protein levels are maintained too low for
its growth supressory functions to be manifested, due to the presence and function of the E6
protein. Increased steady state p53 levels in the revertants despite the presence of the E6 protein
correlate precisely with the reversion of the transformed phenotype.
Ectopic expression of the wild-type p53 gene by retroviral integration was shown to
decrease the clonigenicity if the Hela cell in soft agar by a hundred fold. The p53 gene in HeLa
ATCC CCL2 has been previously characterized as wild-type. Mutation in the p53 cDNA's from
HeLa and revertants has not been detected by RNAase protection assay or direct sequencing.
Increased protein levels of p53 protein in the revertants as compared to HeLa were thus
anticipated and found to result in a correspondingly differential manifestation of wild-type p53
function between the three cell lines. First, in the revertants as in non-transformed cells carrying
the wild-type p53 gene, p53 protein is inducible upon treatment with Actinomycin D and y-
irradiation with kinetics of induction and induced p53 protein levels both being at least ten-fold
higher than in Hela. Secondly, p53-specific transcriptional activity is detectable in the revertants.
Specifically, transcription of the chloramphenicol acetylatransferase (CAT) gene driven from a
promoter with multiple p53 consensus binding sites and a TATA box is detectable by CAT
enzyme assay only in the revertants and not in HeLa. Treatment with Actinomycin D and y-
irradiation inreases the transactivating activity of endogenous p53 in the revertants thirty-fold.
Moreover, downstream effectors of the transcriptionally active p53, namely the waf-l and gadd-
45 genes, are expressed in the revertants but not in HeLa. Expression of the gadd-45 mRNA is
constitutive in the revertants while waf-1 mRNA is inducible by irradiation. p53-specific DNA
binding activity in EMSA assays is also inducible by y-irradiation and actinomycin D in the
revertants and not in HeLa cells. Taken together, studies of the functional properties of
endogenous p53 in revertants and HeLa correlate the transcriptional activity of p53 with the
reversion from cervical carcinoma and offer valuable evidence that the transcriptional properties
of the wild-type p53 contribute to its role in growth regulation.
An in vitro ubiquitination-degradation system was used to investigate the causes of
increased p53 protein in the revertants. It was shown that differential targeting of the p53 protein
for proteolysis occurs between HeLa and revertants since ubiquitination-dependent degradation of
in vitro translated p53 protein is faster upon incubation with HeLa than with revertant cell lysate.
This differential degradation of p53 in revertant cell extracts resulted from incomplete
ubiquitination of the p53 protein. Protein-protein interaction studies in HeLa and revertants
showed that p53-E6 binding in HeLa but not ine either revertant suggesting that the differential
degradation of p53 in he revertants was caused by loss of E6 function. Furthermore p53 in HeLa
and HA was associated with the cell cycle regulator p34cdc2, while in the HF cell line this
association was undetectable. p34cdc2 has been previously characterized as a modulator of p53
phosphorylation both in vitro and in vivo and phosphorylation of p53 at the p34cdc2 site has been
found necessary for the ubiquitin-dependent degradation of the p53 protein. Thus, in the HF cell
line, differential degradation of endogenous p53 may result from the failure of p53 to associate
with the cell cycle regulator p34cdc2 and be phosphorylated by it.
Further characterization of the HeLa revertants included protein-protein interaction
studies in the Rb pathway that showed differential binding of Rb to the transcription factor E2FI.
Cell-cycle dependent binding and inhibition of this transcription factor is a known growth
suppressory function of Rb. This result suggests that a common regulator of the p53 and Rb
pathway may have been the target of the reversion event in this cell line. In order to exclude that
reversion had resulted from E6 and/or E7 mutation we expressed ectopically by retroviral
integration HPV-16 E6, E7 or a combination of the two and observed no effect on the revertant
phenotype suggesting that the reversion event has bypassed the E6 and E7 functional pathways.
Ectopic expression of SV40 Large T antigen, however, increased the clonigenicity in soft agar of
the HA but not the HF cell line by -fold. Hence SV40 large T possesses a biochemical function
that can override the cause of reversion in the HA cell line.
Taken together these results clearly establish that functional activation of p53 in two
independent HeLa revertants is the result of change in two different pathways. They also show
the great promise of the HeLa revertant system as a tool for the study of cervical transformation
and for the involvement of the p53 pathway in this type of transformation. The process of
identification of the molecular events that led to p53 and Rb activation in the revertants will
provide valuable insight into the interplay of factors important for cell growth and cell growth
suppression, and may identify potential targets for cancer therapy.
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INTRODUCTION
The HeLa transformant-revertant system
Non-transformed variants (revertants) have been isolated from a wide variety of
oncogene transformed rodent cell lines after chemical mutagenesis (Zarbl et al., 1987, Haynes
and Downing 1988), insertional mutagenesis (Kho and Zarbl, 1991) or after transfection with
genomic DNA or cDNA expression libraries prepared from normal cells (Schaefer et al., 1988;
Noda et al., 1989). Each of the two former techniques would have resulted in the loss of the
transformed phenotype by causing a mutation either within the transforming oncogene itself or
within a transformation effector gene whose products comprise and/or regulate the biochemical
pathways of cell transformation (Boylan et al., 1991; Kho and Zarbl, 1991). A revertant
phenotype could also arise from functional activation or ectopic expression of tumor suppressor
genes. Thus the study of in vitro systems comprising of transformed cells and their non-
tumorigenic variants culminates in identifying the gene or genes that have been the target of
mutation during the reversion event. The ambition in producing such in vitro systems is to
elucidate the mechanisms that lead to or prevent cellular transformation and tumorigenesis.
Transformed cell/ revertant cell systems have been used succesfully to identify the ras suppressor
Krev gene (Noda et al., 1989; Kitayama et al., 1989; Kitayama et al., 1990) and transformation
effector genes (Boylan et al., 1991; Kho et al., 1991; Van Amsterdam et al., 1993).
A major difficulty of the transformed cell / revertant cell approach is the selection of a
phenotypic characteristic that differentiates the few revertant cells that have arisen within the
transformed cell population. Zarbl et al., (1987) have used loss of the prolonged rhodamine 123
dye retention phenotype to isolate revertants of v-fos-transformed Rat-i fibroblasts by
fluorescence-activated cell sorting (Zarbl et al., 1987). While prolonged retention of rhodamine
123 is limited to v-fos (Zarbl et al., 1987) and v-jun (our unpublished results) transformed rodent
fibroblasts, this phenotype is common to almost all human carcinoma cell lines (Summerhayes et
al., 1982). Thus the loss of prolonged rhodamine retention could be a universally acceptable
procedure for the isolation of revertants of transformed human cells. We chose HeLa, a human
epithelioid adenocarcinoma of the cervix, as the parental cell line from which to isolate revertants
by selection for loss of prolonged rhodamine retention. Two stable revertant cell lines, HA and
HF, have thus been isolated from the earliest available HeLa isolate, clone ATCC CCL2
following exposure to the mutagen ethylmethylsulfonate. The revertant cell lines have lost the
ability to grow in suspension culture or in soft agar medium, as well as the ability to form tumors
in nude mice. The transformed cell lines of the rodent systems that had been studied previous to
our HeLa system were typically generated by the introduction of an activated oncogene such as
ras orfos in an established cell line and therefore the genetic changes leading to transformation
are partially defined. The HeLa cell, however, was a fully transformed cell derived from a
malignant, metastatic, lethal tumor. Cellular transformation is the hallmark of carcinogenesis and
the phenotypic sum of multiple genetic abberations. In general, the extent of malignancy of a
tumor is thought to directly correlate with the number of genetic abberations accumulated. Thus
the genetic abberations in Hela would be far greatly complicated as compared to that of their
rodent counterparts. To our advantage, however, as the first human cell line to have been
propagated in cell culture, HeLa has been extensively characterized and used in numerous studies.
More importantly, in recent years substantial research progress has shed light into the etiology of
cervical carcinoma and has implicated biochemical pathways which are being actively
investigated by numerous laboratories. In a way, what is known about cervical carcinoma could
be considered the equivalent of knowing the identity of the transforming oncogene in the rodent
systems, and thus justifies the selection of HeLa for the studies presented in this thesis.
Cervical Carcinoma and Human Papilloma Virus Transforming Viral Oncogenes
Cervical carcinoma, is the second most common gynaecological cancer. It is
characterized by high metastatic potential and poor prognosis and claims about 500,000 lives
world-wide every year. Epidemiological data have linked a sexually transmitted agent in the
development of this type of cancer Between 85% and 95% of cervical carcinomas have been
found to contain integrated viral genomic sequences of Human Papilloma Viruses -16, -18, -31,
-33 and -39 the so called "high risk" HPV's (Durst et., 1983; zur Hausen, 1987 and 1991;
Schiffman et al., 1991). In benign and premalignant lesions the HPV DNA exists episomally,
while in malignant lesions and cervical carcinoma cell lines, HPV DNA is integrated, often in
multiple copies, with preservation of the E6 and E7 open reading frames and disruption or
deletion of the El and E2 genes (Schneider- Gadicke et al., 1988; Durst et al., 1987; Popescu et
al., 1989; Lazo et al., 1989; Sousa et al., 1990). In some cases, which include the HeLa cell line,
integration occurs in the vicinity of oncogenes - usually c-myc - and leads to their increased
expression (Schneider- Gadicke et al., 1988). Chromosomal instability has been observed in
HPV associated cancers with an increase from 33% to 82% in aneuploid cells in cervical lesion
progressing from subclinical HPV infection through the stages of cervical intraepithelial
neoplasia (Reid et al., 1984). The E6 and E7 genes of the "high risk" HPVs have been implicated
as essential factors in cervical carcinogenesis because of their presence and expression in cervical
carcinomas and carcinoma cell lines (Baker et al., 1987; El Awady et al., 1987; Schneider-
Gadicke and Schwarz, 1986; Schwarz et al., 1985; Seedorf et al., 1987; Smotkin and Wettstein,
1986; Roggenbuck et al., 1991). Numerous studies have demonstrated the transforming properties
of the two viral oncogenes (reviewed in Mansur and Androphy, 1993). Most importantly, HPV-
16 and -18 E6 and E7 can immortalize primary human keratinocytes (Kaur et al, 1988; Hawley-
Nelson etal.. 1989; Munger et al., 1989; Hudson et al., 1990; Barbosa et al., 1991; Halbert et al.,
1991; Schiller et al., 1989) and their maintained expression has been reported as both necessary
and sufficient for tumorigenicity and full blown transformation (Munger et al. 1989, Bosch et al.,
1990, Miyasaka et al., 1991). Furthermore, ectopic expression of HPV -16 and -18 E6 and E7
genes alone in primary human keratinocytes is sufficient to induce aneuploidy (Hawley-Nelson et
al., 1989). Thus, current theory holds that non-productive HPV infection is an early event in
carcinogenesis, that contributes to deregulation of growth as well as to the genomic instability
responsible for further progression towards malignancy.
Human papilloma viruses belong to the family of small DNA viruses that express genes
which can function as dominant oncogenes in biological systems of in vitro transformation,
although it should be noted that human papilloma viruses are the only small DNA viruses to have
been implicated in tumorigenesis in their natural host. By the time a link was established between
human papilloma viruses and cervical carcinoma, significant progress had been achieved in
understanding the biochemical and transforming properties of viral oncogenes of the small DNA
viruses and particularly SV40 Large T and the Adenovirus E1A and E1B. Most of what we now
understand about the biochemical and biological function of the E6 and E7 proteins has been
investigated by analogy to SV40 Large T and Adenovirus EIA and E1B. Thus the transforming
functions of the E6 and E7 are largely attributed to their respective binding and inactivation of
the p53 and Rb tumor suppressor proteins (Werness et al., 1990; Munger et al., 1989; Dyson et
al., 1989). Like SV40 large T and Adenovirus E1A E7 has been shown to inhibit Rb binding to
E2F a transcription factor involved in control of cell proliferation (Nevins, 1991; Nevins, 1992 ;
Morris et al., 1993 ; Hiebert et al., 1993; Hiebert et al., 1992; Bagchi et al., 1990; Pietenpol et al.,
1990; Pietenpol et al., 1991; Sarnow et al., 1982). Like SV40 large T and Adenovirus E1B
(Deppert et al., 1989; Deppert et al., 1989; Tack et al., 1989; Tack et al., 1992 ; Wang et al., 1989;
Yew et al., 1992), E6 binds p53 but rather than increasing its half-life as its two former
counterparts , E6 targets p53 for degradation through a novel ubiquitination pathway (Scheffner
et al., 1992; Scheffner et al., 1992; Scheffner et al., 1993). Athough E6 and E7 function is not
limited to p53 and Rb binding, these are the single properties known to differentiate the high risk
HPVs from the low risk HPVs and are thus considered the crux of their transforming function. An
important point suggested by experimentation on both the relative transforming (Halbert et al.,
1992) and transactivation properties (Storey et al., 1990; Munger et al., 1991) of the low risk
versus the high-risk HPVs is that their differences are related to dose rather than to a qualitative
difference in function.
Both the E6 (Schiller et al., 1984; Grossman et al., 1989; Barbosa et al., 1989) and E7
(Miyasaka et al., 1991; Greenfield et al., 1991; McIntyre et al., 1993; Takami et al., 1992)
proteins are nuclear phosphoproteins containing the Cys-x-x-Cys motif known as zinc finger
necessary for protein-protein interactions -including dimerization- that characterize and regulate
the activiy of many cellular transcription factors. Figure 1.2 is a schematic representation of the
E7 and E6 proteins and key features in their amino acid sequences.
Like adenovirus E1A, the E7 protein has also been shown to bind p107 (Dyson et al.,
1992), an Rb-like protein that regulates members of the E2 family of transcription factors other
than E2F-1 and acts at different stages in the cell cycle (Jones, et al., 1990). The region of p107
binding overlaps with but is not identical to the Rb binding domain. HPV-16 E7 has also been
shown to bind cdk2 and cyclin A. Structural homology between E7 and E1A in the carboxy
terminus pointed out a casein kinase II recognition site (Barbosa et al. 1990, Firzlaff et al., 1991)
and E7 was found to be phosphorylated at serines 31 and 32 within this CKII site. High risk E7 is
more highly phosphorylated than low risk E7 and a preference of Rb for the fully phosphorylated
E7 may explain the differences in Rb binding between low risk and high risk E7 (Gage et al.,
1990). Like Adenovirus EIA, E7 can transactivate the E2 promoter (Phelps et al., 1988; Phelps et
al., 1987) apparently through release of E2F from its complex with Rb (Watanabe et al., 1990;
Edmonds and Vousden, 1989; Schiller et al., 1990; Phelps et al., 1989; Phelps et al., 1992).
Consequently the CKII site is important to the transactivation function of E7 (Storey et al., 1990;
Watanabe et al., 1990; Edmonds and Vousden 1989; Schiller, J.T., Phelps et al., 1989). Again in
an Rb-dependent manner (Banks et al., 1990) and much like E1A, E7 can induce DNA synthesis
in quiescent rodent cells (Banks et al., 1990a; Banks et al., 1990b; Rawls et al., 1990). E7 is
considered to be primarily responsible for the chromosomal instability associated with HPVs
since its introduction in human keratinocytes was shown to produce cell lines with an extended
life span and ploidy and chromosomal aberrations similar to those seen in cells transformed by
the full length of the HPV genome (Hashida and Yasumoto, 1991). It is inknown however
whether the genomic instability is related to the ability of E7 to induce DNA synthesis or an
indirect result of of the E7- induced cell growth.
E6 is a strongly basic nuclear phosphoprotein with two putative zinc fingers. Thus, E6
has the characteristics of a DNA binding factor, although no specific sequence interactions have
been reported reproducibly (Schiller et al., 1989; Gius et al., 1988; Imai et al., 1989). Since both
the SV40 and Adenovirus viral oncogene products targeted Rb and p53, once it was shown that
E7 bound Rb, E6 became the reasonable candidate to bind p53. In mixing experiments of in vitro
translated E6 and p53, E6 was co-immunoprecipitated by an anti-p53 antibody (Scheffnner et al.,
1990). It has been postulated that the first zinc-binding finger of HPV-16 E6 is necessary for
targeting of p53 for degradation and the second is responcible for p53 binding (Crook et al.,
1991a). Binding of E6 to p53 occurs in a bimodal complex and is dependent upon the presence of
a a 100kDa polypeptide, termed E6-AP (Scheffner et al., 1993) which has recently been cloned
(Huibregtse et al., ) and found to function as a ubiquitin ligase (Scheffner et al., 1993).
Most of what we know about the function of E6 is related to its interaction with the p53
gene product. HPV-16 and -18 E6 have been immunoprecipitated from carcinoma cell lines with
integrations of the respective HPV DNA (Androphy et al., 1987; Banks et al., 1987; Banks et al.,
1987; Sedman et al., 1991; Androphy et al., 1985) as well as from HPV-immortalized
keratinocytes (Hawley-Nelson et al., 1989; Sedman et al., 1991; Halbert et al., 1991) and in all
cases its levels of expression appears were very low and "almost certainly much less than p53 in a
cell" as quoted by Mansur and Androphy. Since E6 targets p53 for degradation without being
itself degraded, even low levels are enough to lower p53 in the HPV containing cell lines to levels
that although detectable, release the cell from the growth inhibitory effects of p53. By
immunoblot the levels of p53 in HPV-16 E6 expressing keratinocytes do not always differ
significantly from their primary cells of origin but the half-life of the p53 protein is always
reduced (Band et al., 1990; Hubbert et al., 1992). Damage to DNA in both prokaryotic and
eukaryotic cells leads to transient delays of cell cycle progression with blocks in the passage
from the G1 phase to S and from the G2 phase to M (Tolmach et al., 1977; Painter and Young,
1980; Lau and Pardee, 1982; Weinert and Hartwell, 1988; Kaufmann et al., 1991; O 'Connor et
al., 1992). Kastan et al., (1991) have implicated p53 in GI arrest following y-irradiation.
Comparison between primary cells and cell lines transformed by HPV-16 DNA has shown that
high risk E6 can interfere with this p53-mediated block in Gl upon DNA damage (Kessis et al.,
1993). HPV-16 E6 and to a lesser extent HPV-6 E6 have also been shown to counteract the
repressive effects of p53 on p53-repressible promoters in cotransfection assays (Lechner et al.,
1992). The inhibition of p53-dependent repression was fully conferred by E6 mutants defective
for p53 degradation but not for p53 binding. Conversely, HPV-18 and -16 E6 have been shown to
transactivate basal promoters and mutations within the p53-binding zinc finger reduced E6
dependent transactivation (Sedman et al., 1991; Crook et al., 1991; Gius et al., 1988; Desaintes et
al., 1992). However, mutations that abolished p53 binding in vitro remained transcriptionally
competent in 3T3 cells suggesting that E6 transactivation may not be p53-dependent.
Biochemical comparisons between the high risk and low-risk HPV E6 are less conclusive with
respect to relevance to transformation than the same type of studies carried out for the E7 protein.
While the Howley group has never been able to detect E6-p53 binding between low risk E6 and
p53 (Scheffner et al., 1992) and have shown that only HPV-16 and -18 can target p53 for
degradation in an ATP and ubiquitin dependent manner (Scheffner et al., 1990) they have later
shown that HPV-6 -11 and -16 E7/E6 fusion proteins of which the E7 portion can bind an Rb
peptide, all target the Rb peptide for degradation. The Vousden group has shown that HPV-6 E6
can bind p53 -albeit with lower affinity than HPV-16- but it cannot target p53 for degradation
(Crook et al., 1991). Finally, the transactivation properties of the high and low risk HPV E6
appeared to be equally high (Sedman et al., 1991; Crook et al., 1991; Gius et al., 1988; Desaintes
et al., 1992). Recently, two groups have reported that a number of other cellular factors can be
bound by a glutathione column loaded with GST-E6 (). However, the identity of these proteins
and the significance of their binding to E6 remains unknown.
Cervical carcinoma, Rb and p53
Rb and p53 are common targets of the viral oncogenes of the small DNA animal viruses
(Kaelin et al., 1990; Ludlow et al., 1989; Schmieg et al, 1984). Full blown transformation can be
conferred by these viruses to established cell lines only when both Rb and p53 are associated with
a viral oncogene. The association is thought to inactivate the normal tumor suppressor functions
of Rb and p53. Deregulation of both normal Rb and normal p53 function is a requirement in
cervical carcinoma: all the cervical carcinoma cell lines tested express "high risk" HPV E6 and
E7 or have sustained mutations in both Rb and p53 (Scheffner et al., 1991; Crook et al., 1992a;
Crook et al,, 1992b; Crook et al., 1991).
The Rb tumor suppressor gene is a nuclear phosphoprotein with the biochemical
properties of a transcription factor and the functions of a cellular growth regulator. Rb protein is
expressed throughout the cell cycle and is a substrate for multiple phosphorylation which occurs
progressively during the cell cycle (Firzlaff et al., 1989; Barbosa et al., 1990; Firzlaff et al., 1991,
Taya et al., 1989; Thomas et al., 1991; Hinds et al., 1992; Dowdy et al., 1993; Yen et al., 1994;
Zhang et al., 1994). Association between Rb and viral oncogenes prevents Rb binding to E2F a
transcription factor involved in the control of cell proliferation (Sarnow et al., 1982; Bagchi et al.,
1990; Pietenpol et al., 1990; Chellappan et al., 1991; Nevins et al., 1991; Pietenpol et al., 1991;
Hiebert et al., 1992; Nevins, 1992; Nevins, 1992; Hiebert et al., 1993; Morris et al., 1993).
Complex formation between Rb and E2F-1 prevents the latter from activating promoters of genes
such as c-myc which are important signals for growth (Kley et al., 1992; Lechner et al., 1992). It
was discovered that rather than simply inhibiting transcription Rb- E2F1 complex formation turns
a positive regulatory element within the c-myc promoter into a negative one (). Rb
phosphorylation modulates Rb-E2F binding throughout the cell cycle (Chellappan et al., 1991;
Chittenden et al., 1991; Helin et al., 1992; Shirodkar et al., 1992) and is in general thought to play
a pivotal role in the regulation of Rb tumor suppressor functions (Mittnacht et al., 1991;
Mittnacht et al., 1991; Cobrinik et al., 1992; Hatakeyama et al., 1994; Mittnacht et al., 1994).
Viral oncogenes as well as E2FI bind the underphosphorylated form of Rb which predominates in
the G 1 phase of the cell cycle and during growth arrest. Inhibition of E2F-Rb complex formation
by the viral oncogenes is thought to allow passage from the G1 phase to S, the phase of DNA
synthesis. Most of the Rb literature refers to the underphosphorylated 105 kDa Rb species
predominant in G1 as the active form of the Rb protein that inhibits the GI/S transition, as
opposed to the inactive phosphorylated 110 kDa form. However, the continuation of Rb
phosphorylation beyond the Gl/ S phase suggests the possibility of multiple Rb functions
regulated by various degrees of phosphorylation. Regulation of Rb phosphorylation is at least in
part mediated through the paracrine growth factor TGF 1I (Seto et al., 1992). TGFP1 effects on
cell growth vary according to cell type but in primary human keratinocytes, the system that has
been most widely used for the study of E6 and E7, treatment with TGFP1 leads to cessation of
growth and a concurrent decrease in c-myc transcription (Deb et al., 1992). Alteration of the state
of the Rb protein is thought to play a role in both the growth arrest and the down regulation of c-
myc expression (Seto et al., 1992).
The p53 tumor suppressor gene is currently the most commonly mutated gene in human
cancers, with seventy percent of all tumors and tumor cell lines examined carrying an altered p53
gene sequence. The p53 mutations are most commonly missence point mutations occuring within
the conserved domains of the p53 protein and result either in loss of growth-suppressor or -most
often- in gain of growth-promoting function (Bargonetti et al., 1991; Kern et al., 1991; Kern et
al., 1991; Zambetti et al., 1991; Bargonetti et al., 1992; Bargonetti et al., 1992; Farmer et al.,
1992; Zambetti et al., 1992; Zambetti et al., 1993; Olson et al., 1994). Several sites where
mutations are detected more frequently have been characterized as mutation hot spots and include
codons 175, 248, 273 and 281 (Hollstein et al., 1991; Vogelstein, 1990; Levine, 1991). Different
tumor tissue types show different bias with respect to mutation site. For example mutation in
codon 175 is common in colon carcinoma but never detected in lung. Germ-line p53 mutations
have also been detected in families with high cancer incidence in multiple tissues, a condition
known as the Li-Fraumeni syndrome. The germ cells of these Li-Fraumeni patients are
heterozygous for mutant and wild-type p53 while their tumors are homozygous for mutant p53
(Malkin et al., 1990 and 1992; Srivastana et al., 1990 and 1992; Togutsida et al., 1992; lavarone
et al., 1992; Li and Fraumeni 1969). Elevated wild-type p53 expression supresses the
transformed phenotype of colon carcinoma, osteosarcoma and breast carcinoma cell lines (Baker
et al., 1990; Diller et al., 1990; Mercer et al., 1990; Chen et al. 1991; Cheng et al., 1992; Wang et
al., 1993). The exact mechanism or mechanisms through which wild-type p53 functions in
tumor/growth supression is not known, although p53 involvement in response to DNA damage
(Kastan et al., 1991; Kuerbitz et al., 1992; Kessis et al., 1993; Lowe et al., 1993; Lowe et al.,
1994; Slebos et al., 1994), cell cycle control (Kastan et al., 1991; Perry et al., 1993; Slichenmyer
et al., 1993; Chen et al., 1994; Slebos et al., 1994), transcriptional activation (Kern et al., 1991;
Kern et al., 1991; Zambetti et al., 1991; Kern et al., 1992; Zambetti et al., 1992; Zambetti et al.,
1993), transcriptional repression (Ginsberg et al., 1991; Santhanam et al., 1991; Subler et al.,
1992; Kley et al., 1992; Chin et al, 1992; Lechner et al., 1992; Seto et al., 1992) and DNA
replication (Wang et al., 1989; Friedman et al., 1990; Bargonetti et al., 1991; Bargonetti et al.,
1992; Friedman et al., 1993; Reynisdottir et al., 1993; Wang et al., 1993; Moses et al., 1994) have
all been implicated. An ongoing hypothesis which explains early involvement of p53 in
carcinogenesis views p53 function as a safeguard of the integrity of the genome. Thus, when p53
function is normal, cells that cannot replicate properly -due either to lack of metabolites or to
extensive DNA damage- stop dividing or die. However, when p53 function is perturbed offended
cells can suffer further oncogenic changes and develop into cancer cells. p53-specific
transcriptional activation of genes controlling the cell cycle, specifically the cyclin inhibitor cip-
l/waf-1 (el Deiry et al., 1993) provides a direct link between p53 and the control of cell
proliferation. Transcriptional activation and DNA binding are specific to wild-type p53 (Kern et
al., 1991; Kern et al., 1991; Kern et al., 1992) as is the induction of the cyclin kinase inhibitor
cip- l/waf-1 after y-irradiation (Scott Lowe, personal communication). Thus it is thought that the
transcription factor properties of wild-type p53 are essential for its role in cell growth control.
p53 is a 393 amino acid nuclear phosphoprotein whose structure resembles a transcription
factor (Mathlasewski et al., 1984; Pennica et al., 1984; Soussi et al., 1987). The amino- terminus
is highly acidic with a net charge similar to Herpes Simplex virus VP16 and yeast GAL-4. The
carboxy- terminus is strongly basic as would be expected from a DNA binding domain and
contains three nuclear localization signals (NLS) (Shaulsky et al., 1990). The predominant NLS is
located adjacent to serine 315 (312 for mouse and rat p53) which is phosphorylated in vivo and in
vitro by cdc2p34 (Milner et al. 1990; Sturzbecher et al., 1990; Bischoff et al., 1990). Thus
phosphorylation of this serine residue could influence p53 subcellular localization and biological
activity in a cell cycle dependent manner. Phosphorylation has also been speculated to be the
mechanism through which p53 is stabilized in response to DNA damage or cellular stress. Lin
and Desiderio have shown that phosphorylation of Serine 315 inhibits the ubiquitin dependent
degradation of p53. The p53 has also been documented to be a substrate for casein kinase II () and
the DNA () polymerase associated kinase.
The major mechanism of control of p53 expression appears to be through protein
stability (post-transcriptional modification; Oren et al 1981, Reich et al. 1981). The hypothesis
that HPV E6 targets p53 for ubiquitination was formulated when HPV-16 and -18 were found to
bind E6 in vitro and cervical carcinoma cell lines with HPV integrations that express the wild-
type p53 mRNA but show low levels of p53 protein . HPV -16 and -18 E6 were consequently
found to induce ATP and ubiquitin-dependent degradation of p53 in rabbit reticulocyte lysates
(Scheffner et al.,1990) and a novel ubiquitin-dependent pathway has been implicated in p53
degradation (Scheffner et al., 1992a; Scheffner et al., 1992b; Scheffner et al., 1993). Ubiquitin-
dependent degradation of p53 in vitro has been more recently shown to take place in the absence
of E6 (Ciechanover et al., 1994). Wild-type p53 is a relatively short-lived protein with a half-life
of about 3 hours in normal cells and twenty minutes in transformed cells. Endogenous levels of
p53 protein are low in certain cell types and vary two- to four-fold between various stages of the
cell cycle in p53 expressing cells. It is therefore possible that ubiquitin-dependent proteolysis is
involved in the regulation of p53 protein expression in non-transformed cells and that E6 analogs
may exist in such cells.
p53 was ound to transactivate the muscle creatine kinase (MCK) gene (Weintraub et al.,
1993) and a p53 binding site was defined within the MCK promoter. p53 was subsequently
shown to bind DNA both specifically (Kern et al., 1991b; Bargonetti et al., 1991) and non-
specifically (Steinmeyer et al., 1988; Kern et al., b, 1991). When the p53 response element was
included in basal promoters and placed 5' of the CAT reporter gene, the reporter was
transactivated when co-transfected with wild-type p53 (Zambetti et al..,1992; Kern et al., 1992;
Farmer et al., 1992). Furthermore when mutant and wild-type p53 where co-expressed there was a
dominant effect of the mutant p53 that was related to decreased binding of presumed wild-type
:mutant oligomers to DNA (Kern et al. 1992). A number of promoters like those of c-fos and c-
jun have now been shown to be repressed by p53. Repression does not occur though a p53
binding site and the promoters repressed by p53 are seemingly unrelated, indicating that a more
general mechanism for suppression may be operative (Ginsberg et al., 1991; Santhanam et al.,
1991; Subler et al., 1992; Kley et al., 1992; Chin et al, 1992; Lechner et al., 1992). Wild-type p53
transfected into p53 null cell lines was shown to supress a minimal promoter including only the
adenovirus major late TATA element and the terminal deoxynucleotidyl transferase initiator. p53
was subsequently found to be able to complex with the TATA binding protein (TBP) and has
been hypothesized to exert its supressive effects through the core transcriptional machinery (Seto
et al., 1992).
Damage to DNA in both prokaryotic and eukaryotic cells lead to transient delays of cell
cycle progression with blocks in the passage from the GI phase to S and from the G2 phase to M.
These blocks are presummed to prevent replication of damaged DNA and segregation of damaged
chromosomes, respectively. p53 protein has been shown to be inducible in mouse fibroblast lines
by treatment with ultraviolet light or UV-mimetic drugs due in large part to increased stability of
the protein. The induction has also been shown to take place in vivo in human skin subjected to
UV. Similar responses have been shown after treatment with y-irradiation or Actinomycin D
(Kastan et al., 1991). Exposure to the inducing agents caused a temporary arrest in the GI of the
cell cycle in cells expressing wild-type p53 but not in cells with mutant p53. Furthermore,
malignant cells lacking endogenous p53 partially restored the ability to arrest in GL after y-
irradiation when they were transfected with a construct expressing wild-type p53, while
overexpression of a mutant p53 in tumor cells with a wild-type endogenous p53 abbrogated the
GI arrest (Kuebritz et al., 1992). Cells derived from patients suffering with Ataxia Telangiectasia
-a disease characterized by hypersensitivity to ionizing radiation, radioresistant DNA synthesis
and a markedly increased incidence of cancer- failed to induce p53 and failed to arrest in Gl,
much in a manner similar to p53-deficient cells (Kastan et al., 1992). These results suggested a
role for p53 in cell cycle control that requires the uninterrupted function of p53 inducing
pathways. In the Ataxia Telangiectasia cells failure to induce p53 protein following y-irradiation
correlated with failure to induce the mRNA of the growth arrest and DNA damage inducible gene
gadd-45, which may be involved in DNA repair. The lack of gadd45-mRNA induction, further
correlated with lack of p53 binding to a site within intron 3 of the gadd45 gene. Zhan et al. 1993
provided further evidence suggesting that p53 involvement in gadd45 induction is specific to y-
irradiation and not other treatments. Thus DNA binding and transactivational properties of p53
were implicated in the response to DNA damage.
But not until the discovery of the cipl/wafl gene had there been a link between the
transcriptional properties of wild-type p53 and cell cycle control. The WAF-1 gene has been
identified by means of its differential induction by wild-type but not mutant p53. The induction is
thought to be mediated by direct transactivation of the waf-1 promoter since the identified p53
binding sites within this promoter can confer p53 specificity to reporter constructs (El Deiry et
al., 1993). WAF-1 was then found to be identical to a gene called CIP-1 which encoded an
inhibitor of cyclin/cyclin kinase complexes (Harper et al., 1993). Evidence has since been
accumulating to verify the hypothesis that induction of p53 upon conditions of cellular stress or
DNA damage leads to inhibitiion of cell cycle progression through the waf-1/cip-1 protein. All
current evidence suggests that wild-type p53 function is absolutely essential to waf-1 induction
(El Deiry et al., 1993).
Previous work has shown that p53 is functional in tetrameric complexes (Friedman et al.,
1993). It appears that during the progression of the cell cycle, the wild-type p53 protein can
assume two conformations, each of which may play a distinct role in the physiological life of the
cell (Ullrich, et al., 1992). One conformation is specific to the wild-type protein and has been
associated with the ability to block cell cycle progression. The other conformation seems to
function in promoting cell proliferation and had originally been distinguishing mutant p53 from
wild-type (Harlow et al., 1981; Yewdell et al., 1986; Gannon et al. 1990, Cook and Milner, 1990).
Milner and coworkers have demonstrated that when mutant and wild-type p53 are co-expressed in
vitro (1:1 molecular ratio) complex formation between wild-type p53 and mutant p53 forced the
wild-type p53 into the mutant conformation. Furthermore, Kern et al. showed that transiently
transfected 175 mutant could reduce the p53 transactivation of reporter constructs in the presence
of cotransfected wild-type p53. The work of Ullrich et al., (1992) showed that the allosteric
effect of mutant p53 may not occur in vivo in the same direct manner as in vitro. In cells
expressing endogenous mutant p53 and an inducible wild-type p53 gene both wild-type/wild-type
p53 and wild-type/mutant complexes exist. In these cells the wild-type p53 can exert its
antiproliferative effect and upon GI arrest no wild type p53 is seen complexed with mutant.
Finally in Saos-2 cells, which lack endogenous p53, simultaneous retroviral transfer and
expression of the wild-type and a dominant mutant p53 genes was able to suppress anchorage
independent growth and tumorigenicity much as expression of wild-type alone. Thus, in the in
vivo contexts examined, wild-type p53 has a dominant effect over the mutants biochemically
defined as dominant.
Cervical transformation and the HeLa/revertant system
The HeLa cells harbor approximately 10-20 copies of HPV-18 DNA per genome
equivalent (Lazo et al., 1987; Lazo et al., 1989; Schwarz et al., 1985) and they express the E7 and
E6 viral oncogenes. Continued expression of the E6/E7 genes has been found necessary for the
maintenance of the transformed phenotype of the HeLa cell (Bosch et al., 1990; Bosch et al.,
1991). The Rb protein was reported to be normal-sized in both its phosphorylated and non-
phosphorylated forms in HeLa (Scheffner et al., 1991). p53 mRNA expression was not inhibited
but the levels of the p53 protein were found to be undetectable (Matlashewski et al., 1986) or very
low while p53 cDNA sequence was wild-type (Scheffner et al., 1991). p53 protein synthesis was,
however, shown to take place when the endogenous p53 protein present was stabilized by
transfection with a mouse mutant p53 and detected by immunoprecipitation (May et al., 1991).
The latter result suggested that p53 is being rapidly degraded in the HeLa cell, presumably via the
E6-mediated ubiquitination pathway.
This Research Thesis describes the initial characterization of non-transformed revertants
isolated from HeLa cells on the basis of prolonged rhodamine 123. Initial phenotypic
characterization of the revertants demonstrated that these cells lost most of the in vitro properties
associated with transformed cells, including a transformed morphology, clonigenicity in semi-
solid medium, and growth in suspension culture (Boylan et al, 1996). Stanbridge and co-workers
have previously carried out somatic cell hybridization experiments using HeLa cells and primary
human fibroblasts and showed that the tumorigenicity of HeLa cells is suppressible (). They have
futher demonstrated that a tumor suppressor gene harbored on the short arm of human
chromosome 11, is able to suppress the tumorigenicity of HeLa cells (Maniatis et al., 1982;
Srivatsan et al, 1986 ; Stanbridge et al., 1986). However, all of the non-tumorigenic cell hybrids
generated from the fusion of HeLa cells and normal human fibroblasts invariably maintained the
in vitro characteristics of the transformed parental Hela. Thus, loss of the tumor suppressor gene
on chromosome 11 is likely to be associated with tumor progression rather than initiation of
carcinogenesis. In contrast, the events that led to reversion in our system may have affected early
pathways of transformation, such as E6 and E7 functional pathways. In rodent transformed cell /
revertant cell systems reversion is often the cause of inactivatng mutation within the transforming
oncogene (). Our knowledge of the involvement of E6 and E7 in cervical transformation makes
each of these genes the analogue of the transforming oncogene in the rodent systems. It was
therefore necessary to examine the possibility of functional inactivation of each of the two
oncogenes.
Continued expression of the E6/E7 genes -which has been found necessary for the
maintenance of the transformed phenotype of the HeLa cell (Schwarz et al., 1985; Schneider-
Gadicke et al., 1986; Schneider-Gadicke et al., 1987; Bosch et al., 1990; Bosch et al., 1991)- was
verified in the revertants. Retroviral transduction of HPV-16 E6, E7 or a combination of the two
had no effect on the revertant phenotype. On the other hand, cell fusion experiments between
HeLa and revertants raised the possibility that a tumor suppressor gene may have been activated
during the reversion process. Since the transforming functions of the "high risk" HPV E6 and E7
are thought to result from their respective binding and inactivation of the p53 and Rb tumor
suppressor proteins (Dyson et al., 1989; Munger et al., 1989; Munger et al., 1989; Werness et al.,
1990) functional inactivation of the E6 and/or E7 could be manifested as activation of either Rb
or p53 tumor suppressors. Such activation could conceivably be caused by the interruption of the
association between the viral oncoprotein and cellular tumor suppressor. Disruption of the
suppressor/inactivatingoncogene association could in turn result from a change in a regulator of
the tumor suppressor or of the relevant HPV oncogene protein. We have thus examined the state
of the p53 and Rb tumor suppressor genes in HeLa and revertant cells.
We found increased steady state levels of wild-type p53 in both revertants despite the
continued presence of the E6 protein. Detectable Rb-E2FI binding in the revertants suggested
functional Rb activation and E7 inactivation, particularly in tthe HF revertant. In addition,
differences in protein-protein interactions in both the Rb and p53 pathways were observed
between HeLa and the revertants. To this point our data had established that reversion of
transformation was the result of functional inactivation of the E6 and E7 pathways in the
revertants. Increase of the levels of p53 was the most consistent and striking difference between
HeLa and the revertants and the remainder of the research presented in this report focused on the
study of the p53 gene product in our system. We have thus shown that wild-type p53 can suppress
the HeLa phenotype. We have further succeeded in establishing that revertant p53 is wild-type
and that wild-type-p53-specific functions are manifested in the revertants but not in HeLa.
Finally, we have shown that decreased p53 proteolysis is the probable cause of increased p53
levels in the revertants with respect to HeLa. Loss of E6 function and of ubiquitin dependent
degradation have been identified as the cause for functional p53 activation and a testable
hypothesis has been formulated about the involvement of p34cdc2 in the functional pathway of
the E6 viral oncogene. Although the extent of p53 contribution to the revertant phenotype remains
to be assessed, the research presented here emphasizes the central role of the HPV and p53
pathways in cervical transformation and offers in vivo evidence for the link between the
transcriptional activity of p53 and the control of cell growth. Most importantly, this work
suggests that interference with the HPV functional pathway or activation of the p53 pathway may
help control cervical carcinoma cell growth and may be reasonable approaches to the
development of new therapeutic strategies.
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Abstract
We report the isolation of two non-transformed revertants of the HeLa (ATCC CCL2)
cell line. Revertant cells exhibited a flat non-refractile morphology, failed to grow in suspension
culture, had more than 100-fold lower cloning efficiencies in semi-solid medium and failed to
induce subcutaneous tumors when injected into nude mice. Somatic cell fusion experiments
suggested that revertant cells had sustained a mutation or mutations that resulted in the activation
of a suppressor of transformation. Molecular characterization of these revertants demonstrated
that the HPV-18 sequences present in the parental HeLa cells are retained in the revertants.
Expression of the HPV-18 E6 and E7 at both the mRNA and protein levels were comparable to
those seen in the parental HeLa line. Retroviral transduction of HPV-16 E6, E7or a combination
of the two had no effect on the revertant phenotype, suggesting that loss of the viral oncogenes
was not responsible for loss of the tumorigenic phenotype in either clone. We have investigated
whether the Rb and p53 genes have been reactivated during the reversion process. We found that
increased steady state levels of wild-type p53 in the revertants despite the presence of the E6
protein correlate precisely with the reversion of the transformed phenotype. Differences in
protein-protein interactions in the pathway of p53 and/or Rb among the three cell lines and the
fact that retroviral transduction of the SV40 large T antigen increased clonigenicity in soft agar
HA cell line only by a hundred-fold of the indicate that reversion in the two independent
revertant clones was the result of two distinct events. Rb-E2FI binding in the revertants and
particularly HF suggested functional Rb activation in this clone. Taken together these results
clearly establish that the reversion of transformation in two independent HeLa daughter clones
occured via two distinct mechanisms that result in functional inactivation of the E6 and/or E7
pathways.
Introduction
Non-transformed variants (revertants) have been isolated from a wide variety of
oncogene transformed rodent cell lines after chemical mutagenesis (Zarbl et al., 1987), insertional
mutagenesis (Kho et al., 1991) or after transfection with genomic DNA or cDNA expression
libraries prepared from normal cells (Schaefer et al., 1988; Noda et al., 1989). Loss of the
transformed phenotype can result from inactivation of the transforming oncogene or
transformation effector genes, whose products comprise and/or regulate the biochemical
pathways of cell transformation (Boylan et al., 1991; Kho et al., 1991). A revertant phenotype can
also arise from activation or ectopic expression of tumor suppressor genes.
We have previously used loss of the prolonged rhodamine 123 dye retention phenotype to
isolate revertants of v-fos-transformed Rat-i fibroblasts using fluorescence-activated cell sorting
(Zarbl et al., 1987). While prolonged retention of rhodamine 123 is limited to v-fos (Zarbl et al.,
1987) and v-jun (our unpublished results) transformed rodent fibroblasts, this phenotype is
common to almost all human carcinoma cell lines (Summerhayes et al., 1982). We were
interested in studying revertants of a human tumor cell line and chose as our parental cell line,
HeLa, an epithelioid adenocarcinoma of the cervix. Two stable revertant cell lines, HA and HF,
have been isolated from HeLa (ATCC CCL2) following exposure to the mutagen
ethylmethylsulfonate. The revertant cell lines were selected for their non-transformed
morphology and for loss of prolonged rhodamine retention by fluorescence-activated cell sorting;
they have lost the ability to grow in suspension culture or in soft agar medium, as well as the
ability to form tumors in nude mice. The studies presented in this paper were aimed at identifying
molecular events that may be central to the mechanism of transformation of HeLa and may thus
be causative factors of cervical carcinoma.
Cervical carcinoma, the second most common gynecological cancer is characterized by
high metastatic potential and poor prognosis and claims about 500,000 lives world-wide every
year. Epidemiological data have linked a sexually transmitted agent in the development of this
type of cancer: as many as 90% of cervical carcinoma has been found to contain integrated viral
genomic sequences of Human Papilloma Viruses -16, -18, -31, -33 and -39 the so called "high
risk" HPV's (Durst et al., 1983; zur Hausen et al., 1987; zur Hausen et al., 1991; Schiffman et al.,
1991). In benign and premalignant lesions the HPV DNA exists episomally, while in malignant
lesions and cervical carcinoma cell lines HPV DNA is integrated, often in multiple copies, with
preservation of the E6 and E7 open reading frames and disruption or deletion of the El and E2
genes (Schneider- Gadicke et al., 1988; Durst et al., 1987; Popescu et al., 1989; Lazo et al., 1989;
Sousa et al., 1990). In some cases, which include the HeLa cell line, integration occurs in the
vicinity of proto-oncogenes - usually c-myc - and leads to increased expression of this gene
(Schneider- Gadicke et al., 1988). The E6 and E7 genes of the "high risk" HPVs have been
implicated as essential factors in cervical carcinogenesis by virtue of their presence and
expression in cervical carcinomas and carcinoma cell lines (Baker et al., 1987, El Awady et al.,
1987, Schneider-Gadicke and Schwartz, 1986, Schwarz et al, 1985, Seedorf et all 1987, Smotkin
and Wettstein, 1986, Roggenbuck et al. 1991). Numerous studies have demonstrated the
transforming properties of the two proteins (reviewed in Mansur and Androphy, 1993). Most
importantly , HPV-16 and -18 E6 and E7 can immortalize primary human keratinocytes (Kaur et
al, 1988; Hawley-Nelson etal.. 1989; Munger et al., 1989; Hudson et al., 1990; Barbosa et al.,
1991; Halbert et al., 1991; Schiller et al., 1989) and their maintained expression has been reported
as both necessary and sufficient for tumorigenicity and full blown transformation (Munger et al.
1989, Bosch et al., 1990, Miyasaka et al., 1991). The transforming functions of the E6 and E7 are
thought to result from their respective binding and inactivation of the p53 and Rb tumor
suppressor proteins (Wernesset al., 1990 ; Munger et al., 1989; Dyson et al., 1989). Rb and p53
are common targets of the viral oncogenes of the small DNA animal viruses (Kaelin et al., 1990;
Ludlow et al., 1989; Schmieg,et al., 1984). Full blown transformation can be conferred by these
viruses to established cell lines only when both Rb and p53 are associated with a viral oncogene.
The associations with viral oncogenes are thought to inactivate the normal tumor suppressor
functions of Rb and p53. Specifically, association of Rb with SV40 large T, Adenovirus E1A and
E7 has been shown to inhibit Rb binding to E2F a transcription factor involved in control of cell
proliferation (Nevins, 1991; Nevins, 1992; Morris et al., 1993; Hiebert et al., 1993; Hiebert et al.,
1992; Bagchi et al., 1990; Pietenpol et al., 1990; Pietenpol et al., 1991; Sarnow et al., 1982).
Association of SV40 large T and Adenovirus E1B with p53 binds and inactivates p53 (Deppert et
al., 1989; Deppert et al., 1989; Tack et al., 1989; Tack et al., 1992; Wang et al., 1989; Yew et al.,
1992) but results in p53 stabilization, while HPV E6 is thought to inactivate p53 by targeting it
for degradation through a novel ubiquitination pathway (Scheffner et al., 1992; Scheffner et al.,
1992; Scheffner et al., 1993). Deregulation of normal Rb and p53 function appears to be a
requirement in the pathogenesis of cervical carcinoma: all the cervical carcinoma cell lines tested
express "high risk" HPV E6 and E7 or have sustained mutations in both Rb and p53 (Scheffner et
al., 1991; Crook et al., 1992; Crook et al., 1992; Crook et al., 1991).
The Rb tumor suppressor gene is a common target of DNA viral oncogenes namely the
SV40 large T, adenovirus ElA and "high risk"-HPV E7. Rb tumor suppressor functions are
abbrogated (Schmieg et al., 1984; Ludlow et al., 1989; Munger et al., 1989; Kaelin et al., 1990).
Rb protein is a substrate for multiple phosphorylation which occurs progressively during the cell
cycle (Firzlaff et al., 1989; Barbosa et al., 1990; Firzlaff et al., 1991, Taya et al., 1989; Thomas et
al., 1991; Hinds et al., 1992; Dowdy et al., 1993; Yen et al., 1994; Zhang et al., 1994).
Association between Rb and viral oncogenes prevents Rb binding to E2F, a transcription factor
involved in control of cell proliferation (Sarnow et al., 1982; Bagchi et al., 1990; Pietenpol et al.,
1990; Chellappan et al., 1991; Nevins et al., 1991; Pietenpol et al., 1991; Hiebert et al., 1992;
Nevins, 1992; Nevins, 1992; Hiebert, 1993; Morris et al., 1993). Rb phosphorylation modulates
Rb-E2F binding throughout the cell cycle (Chellappan et al., 1991; Chittenden et al., 1991; Helin
et al., 1992; Shirodkar et al., 1992) and is generally thought to play a pivotal role in the regulation
of Rb tumor suppressor functions (Mittnacht et al., 1991; Mittnacht et al., 1991; Cobrinik et al.,
1992; Hatakeyama et al., 1994; Mittnacht et al., 1994). Viral oncogenes as well as E2FI bind the
underphosphorylated form of Rb which predominates in the G1 phase of the cell cycle. Inhibition
of E2F-Rb complex formation by the viral oncogenes is thought to allow passage from the GI
phase to S, the phase of DNA synthesis.
The p53 tumor suppressor gene is currently the most commonly mutated gene in human
cancers, with seventy percent of all tumors and tumor cell lines examined carrying an altered p53
gene sequence. Elevated wild-type p53 expression supresses the transformed phenotype of colon
carcinoma, osteosarcoma and breast carcinoma cell lines (Baker et al., 1990; Diller et al., 1990;
Mercer et al., 1990; Chen et al. 1991; Cheng et al., 1992; Wang et al., 1993). The exact
mechanism or mechanisms through which wild-type p53 functions in tumor/growth supression is
not known, although the involvement of p53 in response to DNA damage (Kastan et al., 1991;
Kuerbitz et al., 1992; Kessis et al., 1993; Lowe et al., 1993; Lowe et al., 1994; Slebos et al.,
1994), cell cycle control (Kastan et al., 1991; Perry et al., 1993; Slichenmyer et al., 1993; Chen et
al., 1994; Slebos et al., 1994), transcriptional activation (Kern et al., 1991; Kern et al., 1991;
Zambetti et al., 1991; Kern et al., 1992; Zambetti et al., 1992; Zambetti et al., 1993) and DNA
replication (Wang et al., 1989; Friedman et al., 1990; Bargonetti et al., 1991; Bargonetti et al.,
1992; Friedman et al., 1993; Reynisdottir et al., 1993; Wang et al., 1993; Moses et al., 1994) have
all been demonstrated. An ongoing hypothesis which explains early involvement of p53 in
carcinogenesis views p53 function as a guardian of the genome integrity. Thus, when cells with
normal p53 cannot replicate properly due either to lack of metabolites or to extensive DNA
damage, p53 invokes the cells to stop dividing or die. When p53 function is perturbed however,
offended cells can continue to divide and to accumulate further oncogenic changes that allow
progression towards cancerous growth. p53-specific transcriptional activation of genes
controlling the cell cycle, specifically the cyclin inhibitor cip- /waf-1 (el Deiry et al., 1993)
provides a direct link between p53 and the control of cell proliferation. Transcriptional activation
and DNA binding are specific to wild-type p53 (Kern et al., 1991; Kern et al., 1991; Kern et al.,
1992) as is the induction of cip-1/waf-1 after y-irradiation (El Deiry et al., 1993). Thus, it is
thought that the transcription factor properties of wild-type p53 are essential for its role in cell
growth control.
The major mechanism for control of p53 expression in cells appears to be through protein
stability (post-transcriptional modification; Oren et al 1981, Reich et al. 1981). E6 proteins HPV-
16 and -18 bind p53 in vitro and cervical carcinoma cell lines with HPV integrations carry the
wild-type p53 gene, although the cervical carcinoma cells express the p53 mRNA, but they show
low levels of p53 protein, leading to the hypothesis that HPV E6 targets p53 for ubiquitination
consistent with this hypothesis. HPV -16 and -18 E6 were thus found to induce ATP and
ubiquitin-dependent degradation of p53 in rabbit reticulocyte lysates (Scheffner et al. ,1990), and
a novel ubiquitin-dependent pathway has been implicated in p53 degradation (Scheffneret al.,
1992; Scheffner et al., 1992; Scheffner et al., 1993). Furthermore, there is evidence that
decreasing p53 is essential for transformed phenotypes.
The HeLa cells harbor approximately 10-20 copies of HPV-18 DNA per genome
equivalent (Lazo et al., 1987; Lazo et al., 1989; Schwarz et al., 1985 ) and they express the E7
and E6 viral oncogenes. The Rb protein was reported to be normal-sized in both its
phosphorylated and non-phosphorylated forms in HeLa (Scheffner et al., 1991). p5 3 mRNA
expression was not inhibited in HeLa cells, but the levels of the p53 protein were found to be
undetectable (Matlashewski et al., 1986) or very low and p53 cDNA sequence was wild-type
(Scheffner et al., 1991). p53 protein synthesis was shown be normal when p53 protein could be
stabilized by transfection of HeLa cells with a mutant p53 (May et al., 1991), suggesting that
wild-type p53 rapidly degraded in the HeLa cell, presumably via the E6-mediated ubiquitination
pathway.
We have investigated whether inactivation of viral oncogene function has contributed to
the non-transformed phenotype of the HA and HF revertants. We have identified no differences in
the expression of the E6 and E7 genes between HeLa and revertants but found changes that
suggested functional activation of the Rb and p53 patways in the revertants. Our results
established that the reversion from transformation in the two independent HeLa revertants was the
result of two distinct events and suggested inactivation of the E6 and/or E7 pathway with the
consequent activation of the p53 and Rb pathways. Identification of the molecular events that led
to p53 and Rb activation in the revertants will provide valuable insight into the interplay of
factors important for cell growth and cell growth suppression, and may identify potential targets
for cancer therapy.
Materials and Methods
Cell Culture
HeLa CCL2, C4I, C4II, FS4 and Saos-2 cells were purchased from American Type Culture
Collection. A431 cells were kindly provided by Robert Weinberg's Laboratory. C4I and C4II cells
were grown in Waymouth's Medium supplemented with 10% fetal bovine serum (FBS). FS4,
A43 1, and Saos-2 cells were grown in DMEM with 10% FBS. HeLa and revertants were grown
in MEMN + 10% FBS or in MEMN +10% NuSerum (Collaborative Research). Growth in soft
agar was assessed by seeding 1 X 102, 1 X10 3 and 1 X 104 cells in 4 ml of MEMN containing
10% fetal bovine serum and 0.3% molten Difco noble agar. Plates were kept at 40 C for 15 min
before incubation at 370 C in a 5% C02 atmosphere. Plates were fed with 2.0 ml of 0.3% agar
medium every 7-10 days.
Growth in suspension cultures was assessed by seeding approximately 1X 106 cells into
100 ml of MEMN +10% FBS in a 250 ml spinner flask. The flasks were incubated at 370 C in a
5% CO2 atmosphere with continuous stirring. Two flasks of each cell type were grown in parallel
and two iml aliquots were removed from each flask every two days and cell numbers were
determined using a Coulter Counter (Coulter Electronics).
Fluorescence-activated cell sorting and isolation of revertants
Cells were stained by exposure to 10 gg/ml of rhodamine 123 (Sigma) in complete culture
medium at 370 C for 30 min. Cells were then washed 4 times with complete medium, each time
for 30 min at 370 C and were then incubated for an additional 6 to 8 h before preparation for
sorting or analysis. To increase the frequency of revertants, approximately 1 X10 7 cells were
treated with ethane methylsulfonate at a concentration of 3 mM for 18h. The cells were then
allowed to recover for 4 days in normal media before they were harvested by trypsinization,
suspended in MEMN +10% fetal bovine serum, and filtered through 70 Am nylon mesh. Cells
were then stained with rhodamine 123 and the relative fluorescence intensity (rhodamine 123
retention) and relative size (forward angle light scatter) were measured with a FACSTARPlus
fluorescence-activated cell sorter (Becton-Dickinson). Viable cells that did not retain rhodamine
123 were collected using previously described parameters (Zarbl et al., 1987). Colonies visible
after 7 days were again stained with rhodamine 123 and examined directly by epifluorescent
illumination using an inverted microscope. Colonies that failed to retain the dye were isolated
using cloning cylinders and purified by repeated cloning.
Tumorigenicity Assay
The tumorigenic potential of the cell lines was evaluated by injection into athymic (nude) mice
(Charles River). Cells were harvested by trypsinization, washed and suspended in 0.5-1.0 ml of
MEMN. Subcutaneous injections of 1 X 107 cells were done with a 23 gauge needle over the
right rear haunch of weanling animals. Both male and female animals were injected. The sites of
injection were palpated on a weekly basis for the appearance of tumors.
Fusion Hybrid formation and soft agar growth:
HeLa, HF and HA cells were grown to 80% confluence in MEMN+10% Nu Serum. 107 cells of
each cell line were harvested by trypsinization electroporated with 1 g of either PY3 (HeLa) or
pMEXneo (revertants) using a GenePulser apparatus (BioRad). Stable transfectants of HeLa were
then selected in media containing hygromycin at a concentration of 200pg/ml and stable
transfectants of revertants were selected in media containing G418 at a concentration of
200gig/ml. Clones HeLa-PY3-9, HFneolO and HAneol7 were characterized for alkaline
phopshatase activity and used for fusion experiments. The cells from one plate of HeLa-PY3-9
and two plates of HFneolO or from one plate each of HeLa-PY3-9 and HAneol7 were seeded,
plated together, and incubated overnight. They were then washed 2 times with PBS and Iml of
50% polyethyleneglycol (PEG) solution was added. PEG was removed by 5 washes with
Phosphate Buffered Saline (PBS). 5 plates of HeLa X HA and HeLa X HF fusions were generated
altogether. Fusion hybrids were selected in media containing 200gig/ml of both hygromycin and
G418 for four weeks. About fifty colonies were obtained on each PEG treated plate, a total of two
to three hundred colonies per revertant type. Thirty individual colonies were then ring-cloned and
transfered at low density to 24-well plates and some were subjected to a second ring cloning. The
remainder of the original colonies were pulled together and frozen down. The HeLa X revertant
hybrid colonies were maintained in hygromycin and G418 containing medium and transfered
from 24-well plates to 6-well plates and eventually to 10mm dishes at which point they were
switched to medium containing G418 alone. For the anchorage independent growth assay 102,
103 , 104 and 105 cells of HeLa,HF, HA and six independent clones each of HeLa X HF and
HeLa X HA hybrids were plated in soft agar in 35mm dishes. Cells were fed every 3 days. At the
end of 3 weeks colonies were stained with lml tetrazolium violet overnight, then inverted and
dried on 3MM Whatman paper. Colonies were counted from the plates with 105 cells plated. The
clones were characterized for alkaline phosphatase content and rhodamine retention. The results
of these experiments as well as of the soft agar growth assay are reported in Table 1.II.
Antibodies:
Polyclonal antibodies against E7 used for immunoprecipitation and for Western blotting after
immunoprecipitation were a generous gift from Denise Gallaway (FHCRC, Seattle) and Elisabeth
Schwarz (DKFZ, Heidelberg) respectively. Anti-Rb antibodies C-36 and IF8 were purchased
from Santa Cruz Biotechnology; 29C1 was kindly provided by Steve Dowdy (M.I.T.). Anti-HPV-
18/E6 antibody ClX1 and anti-HPV16/18 antibody CP15 used respectively for E6
immunoprecipitation and Western blotting were purchased from Oncogene Science and Santa
Cruz Biotechnology. For the study of complex formation between p53 and other proteins we used
the ImmunoCruz system from Santa Cruz Biotechnology. For Western blotting of p53 we used
the monoclonals DO-i and 1801 from Santa Cruz Biotechnology and Oncogene Science
respectively. For p53 immunoprecipitations with metabolically labeled cell lysates the 1801
antibody was used (Oncogene Science; Ab-1). Monoclonal anti-E2FI and anti-cdc2p34 anibodies
were both from Santa Cruz Biotechnology. Antibodies against p34cdc2 and anti-SV40 were
mouse monoclonals from Santa Cruz Biotechnology and Oncogene Science respectively.
Immunoprecipitations
For immunoprecipitation of E6 we used an E6 lysis buffer (20mM Tris.Cl pH 6.5, 1mM EDTA,
0.25mM EGTA, 0.6% NP-40, 140mM NaC1, ImM DTT). For the immunoprecipitation of Rb, E7
and E2FI we used the E1A lysis buffer (50mM Hepes pH 7.0, 0.1% NP-40, 250mM NaCL).
Aprotinin (30g.g/ml), PMSF (50gg/ml), leupeptin (2gtg/ml), pepstatin (1tg/ml) and Sodium
Orthovanadate (0.1mM; as indicated in figure legends) were added to the appropriate ice cold
lysis buffer prior to cell lysis. Cells growing to 70% confluence were washed twice with PBS,
then 0.5ml of lysis buffer were added per 100mm plate. Cell lysis was carried out on ice, lysates
were removed by scraping and transfered in Eppendorf tubes, then passed through a 22 gauge
needle five times. Lysates were centrifuged in a microfuge at 13,000g for 15 minutes and the
protein content of the retained supernatant was quantitated using either the Sigma Protein
Microquantitation Kit (Sigma Chemicals) or the BCA Protein Microquantitation Kit (Pierce).
0.5mg of protein were used per immunoprecipitation reaction. Reactions were carried out in
duplicate in a total volume of Iml. BSA was added after protein quantitation to a final 2%
weight:volume. Lysates were precleared by preincubation with 50pl of protein A/G conjugated
agarose beads (Santa Cruz Biotechnology) for 1.5hrs, centrifugation for 30sec at top speed in the
microfuge and removal of the supernatant. 1p g of monoclonal antibody was used per reaction or
1LIl of the polyclonal 18E7HX1 (anti E7) or 150g1 of hybridoma supernatant containing the
monoclonal 29C I (anti-Rb). Antibody incubations were carried out for 2.5-4hrs, then 30ml of the
appropriate agarose bead conjugate were added and incubation continued for another 1.5 hrs. The
beads were washed three times with lysis buffer containing protease inhibitors and sodium
orthovanadate but no BSA and once with ice cold PBS with protease inhibitors and sodium
orthovanadate. 30pl of 2X Laemmli sample buffer (4% SDS, 20% glycerol, 200mM DTT or 2%
b-mercaptoethanol, 120mM Tris pH 6.8, 0.002% BPB) were then added and the samples were
stored until gel electrophoresis was carried out. For immunoprecipitations of proteins
metabolically labeled with 35 S-methionine one 100mm plate of each cell line was incubated with
1mCi of Trans Label (ICN; 1000l Ci/mmol) in 2ml of methionine free medium for 1.5hr. Samples
were normalized for TCA precipitable counts after preclearing of the lysate with Protein A/G Plus
Agarose. 7.5X10 6 CPM's were used per reaction in a total volume of lml in the appropriate lysis
buffer.
Gel Electrophoresis:
Samples were boiled for three minutes prior to loading on a Laemmli gel. SDS-PAGE
was carried out in Tris-Glycine buffer system (Harlow, Antibodies a Laboratory Manual) under
constant voltage of 80V in either the Mini Protean (BIO-RAD) or a minigel apparatus from CSB
Scientific Co. for 2 hr, or at 150V on a Protean Apparatus (BIO-RAD) overnight. Protein
standards used were BIO-RAD low molecular weight prestained standards and BIO-RAD wide
range standards which were visualized after transfer by treatment of the Western Blot with the
Aurodye Kit (Amersham) according to the manufacturer's protocol.
Westen Blotting:
Separated proteins were transfered overnight on a PVDF membrane (Immobilon-P; Millipore).
The transfer took place in the cold in the Trans Blotter apparatus (BIO-RAD) under constant
voltage at 60Vin transfer buffer (25mM Tris, 190mM glycine, 20% methanol). Upon completion
of transfer, membranes were blocked in Blotto (5% milk in TBS-T) for 30min, then incubated
with the appropriate antibody dilution in Blotto for thr 15min at room temperature, washed twice
with TBS-T (pH 7.6; 20mM Tris, 137mM NaC1; 0.1% Tween 20) for 10min at room temperature,
incubated with a horseradish- peroxidase-conjugated anti-mouse or anti-rabbit polyclonal
secondary antibody (1:2000 dilution in Blotto; Santa Cruz Biotechnology or Transduction
Laboratories) for 30min and washed twice with TBS-T and once with TBS (same as TBS-T
without the Tween) or PBS. The ECL reagents (Amersham) were used for antigen detection
according to the manufacturer's protocol. Membranes were stripped in 0.2M ethanolamine at
82 0 C for two hours according to the manufacturer's protocol, washed with PBS-0.4% Tween 20
and stained in 0.1% India ink in PBS-0.3%Tween 20 (Harlow book as reference).
Immunoaffinity purification of p53:
p53 protein from HeLa, HA, HF, A431 and Saos-2 cells was purified on a mAb 1801 column
(p53 ImmunoCruz, Santa Cruz Biotechnology) according to the supplier's protocol. Cell lysates
were normalized for protein content prior to run through the column. The experiment has been
repeated 3 times. Protein run through the column ranged from 3-20mg in 2ml of lysate. The final
eluate+Laemmli buffer volume was 600ml and 1/12 of that was used per electrophoresis run.
When 20mg of lysate were used cell lysates were first concentrated on Centriprep-3 columns
(Amicon) prior to passage through the immunoaffinity column.
Retroviral transduction
Retroviral vectors expressing HPV-16 E6, E7 and a hybrid E6/E7 mRNA as well as production of
infectious amphotropic virus and infection of cell lines of interest have been described elsewhere
(Halbert et al., 1991). Infections were kindly carried out in Denise Galloway's Laboratory. The
retroviral vectors LXSN and SS41 which expresses a "supperimmortalizing" mutant of SV40
large T have also been described (Miller et al., Westerman et al., 1996). For the SV40 infections
ecotropic helper-free virus was generated by transient transfection of the highly transfectable
BOSC cell line (60% transfection efficiency) by a highly efficient precipitation with calcium
phosphate method. High titer amphotropic split helper-free retrovirus was generated by
subsequent infection of the mouse TCRIP packaging cell line. Infectious TCRIP supernatant was
then incubated with HeLa and revertants for 24 hours. For all infections, infected cells were
selected in 500pg/ml G418. The pull of G418 resistant cells was tested for growth in soft agar and
molecularly characterized by Western analyses with anti-p53 and anti-SV40 antibodies.
Results
Isolation of revertants:
To increase the probability of isolating non-transformed revertants, HeLa cells were
treated with the alkylating agent, ethyl methanesulfonate (EMS). A concentration of 3 mM EMS
and an incubation time of 18 h was lethal to approximately 30% of the exposed HeLa cells. After
staining with rhodamine 123, the cells were trypsinized and separated by fluorescence-activated
cell sorting (Zarbl et al., 1987). The ability of individual colonies to retain the fluorescent dye was
examined directly by epifluorescent illumination using an inverted microscope. Twenty-seven
colonies that had a persistently low level of dye retention were cloned. Only nine of the colonies
survived the initial cloning procedure. These nine clones were recloned twice using cloning
cylinders.
The individual clones were then tested for their ability to grow in soft agar. Only two of
the clones, designated HA and HF, displayed a reduced cloning efficiency in soft agar (Table
1.1). These two clones were chosen for further characterization. A comparison of the
morphologies of these revertant cell lines with the parental HeLa cell line is presented in Figure
la. In contrast to HeLa cells, the revertant cells had extremely flat and translucent morphologies
that were more characteristic of non-transformed cells.
The revertants were next tested for their ability to grow in suspension cultures. Many
transformed cells, including HeLa can be adapted to grow in suspension cultures. In contrast,
most normal cells must be attached to a solid matrix in order for efficient growth in vitro. The
growth curves for the revertants and HeLa in suspension culture are illustrated in Figure lb. As
expected, HeLa cells quickly adapted to the new growth conditions, while neither revertant clone
grew under these same conditions.
Revertants and HeLa cells were next tested for tumorigenicity after subcutaneous
injection into nude mice. Tumors formed in 4 out of the 5 mice injected with HeLa cells. These
tumors first became palpable after a latency period of six weeks and grew to a size of about 2 cm
by week 12. No tumors were detectable in any of the mice injected with either HA or HF cells
even after a period of 22 weeks (Table I).
Tumor suppressor activation is responsible for reversion of both HA and HF.
Stanbridge and co-workers have previously carried out somatic cell hybridization
experiments using HeLa cells and and primary human fibroblasts. They have demonstrated that
the short arm of human chromosome 11 harbors a tumor suppressor gene that is able to suppress
the tumorigenicity of HeLa cells. In order to determine whether a tumor suppressor had been
activated or whether an oncogene had been inactivated in the HeLa revertants we created
HeLaXRevertant hybrids. Hygromycin resistant clones of HeLa cells were fused with neomycin-
resistant clones of HA and HF revertants. Hybrid clones were selected in media containing both
selection agents, were subcloned at least once, then tested for growth in soft agar and retention of
rhodamine. Throughout cloning, cells were tested for prolonged rhodamine retention and about
75% of the initial clones showed loss of retention. Six of HeLa X HA and HeLa X HF fusion
hybrid clones randomly selected were tested and all of them showed reduced soft agar growth as
compared to HeLa. Fusion hybrids are larger than HeLa and revertants and they are more similar
in morphology and growth to their revertant parent than to HeLa with the exception of clone HF
X HeLa 18.2. Clone HF X HeLa 32 and its subclones have a unique fibroblastic morphology. The
results of these experiments are summarized in Table 1.II. Although we have not yet tested our
hybrids genotypically by caryotyping, the clones under study were maintained under double
selection for long periods of time and subjected to cloning, subcloning and low density plating
throughout the duration of the double selection. Furthermore, as confirmed by standard
temperature stability and enzymatic assay as well as by a protein gel electrophoresis assay HeLa
ATCC CCL2 expresses high levels of the bone/liver/kidney alkaline phosphatase enzyme while
our revertants express lower levels of the placental enzyme (data not shown). The hybrid clones
of reference in this report were also analyzed at the protein level for their alkaline phosphatase
contents and showed either revertant type isozyme profiles or intermediate profiles where both
isozymes were present but the BLK levels were greatly reduced. Finally, the clones examined
had morphologies distinct from each other's and from the parental HeLa and revertant cells. Thus
we do not believe that the clones examined represented co-cultivations of HeLa and revertants.
These results indicated that the revertant phenotype is dominant and led us to believe that a tumor
suppressor gene has been activated in the revertants.
The E6 and E7 protein levels are unchanged between Hela and revertants
Human papilloma virus is considered a causative agent of cervical cell transformation and
continued expression of the E6/E7 genes has been found necessary for the maintenance of the
transformed phenotype of the HeLa cell (Bosch et al., 1990; Bosch et al., 1991). Cell lines and
carcinomas carrying HPV integrations express hybrid mRNA species that encode for both E6 and
E7 proteins, which are then presumably generated by means of differential translational
termination (Schwarz et al., 1985; Schneider-Gadicke et al., 1986; Schneider-Gadicke et al.,
1987). Boylan and Zarbl thus examined whether the levels of the E6-E7 mRNA transcript was
altered in the revertants and found no quantitative or qualitative changes at the mRNA level
(unpublshed data). Immunoprecipitation and immunoblotting experiments showed that the E7
protein levels are also unchanged between HeLa and revertants (Figure ). In these experiments, a
different antibody was used for immunoprecipitation and for immunoblotting to increase the
specificity of substrate recognition. Each experiment was repeated twice. The cervical carcinoma
cell lines C4-I and C4-II, which carry integrated sequences of HPV-18 and express the same E6-
E7 mRNA transcript as HeLa, were used as positive controls. FS4 or Saos-2 which do not carry
HPV sequences and thus do not express HPV E6 and E7 were negative controls cell lines. These
experiments have established that the expression of the E6 and E7 dominant oncogenes have not
been affected at either the mRNA or protein level, but have not addressed the possibility of E6 or
E7 functional inactivation by post-translational modification such as phosphorylation.
The state of p53 in HeLa and revertants
Our cell fusion experiments between HeLa and revertants raised the possibility that a
tumor suppressor gene may have been activated in the revertants (see previous result). On the
other hand, continued expression of the E6/E7 genes has been found necessary for the
maintenance of the transformed phenotype of the HeLa cell (Schwarz et al., 1985; Schneider-
Gadicke et al., 1986; Schneider-Gadicke et al., 1987; Bosch et al., 1990; Bosch et al., 1991) and
the transforming functions of the "high risk" HPV E6 and E7 are thought to result from their
respective binding and inactivation of the p53 and Rb tumor suppressor proteins (Dyson et al.,
1989; Munger et al., 1989; Munger et al., 1989; Werness et al., 1990). This functonal re-
activation of either Rb or p53 tumor suppressors could have occured during the reversion process.
Functional re-activation could have resulted from a change in a regulator of either the tumor
suppressor or the relevant HPV oncoprotein, leading to the interruption of the association
between viral oncogenes and cellular tumor suppressor genes. We have thus examined the state of
the p53 and Rb tumor suppressor genes in HeLa and revertant cells.
Previous reports found the levels of p53 protein in HeLa undetectable or negligible
(Matlashewski et al., 1986; Scheffner et al., 1991). However, we were able to develop a protocol
that allowed us to detect p53 in HeLa and revertants by Western blotting with the anti-p53
antibody DO-1 with or without prior purification of p53 on an immunoaffinity column
(ImmunoCruz system, Santa Cruz Biotechnology, mAb 1801). We attribute the increased
sensitivity of detection of p53 protein in our Western blotting technque, the DO-1 antibody,
which had a better affinity to blotted p53 than any other antibody that we have tested, and use of
the ECL chemilluminescent detection system (Amersham) and an excellent secondary goat anti-
mouse IgG polyclonal antibody (Transduction Laboratories). Immunoaffinity purification and
Western blotting with DO-1 also allows detection of HeLa p53 even when chromophoric
detection by alkaline phosphatase is carried out.
While the levels of p53 in all three cell lines varied depending on cell culture confluence
and nutrient availability, both revertants consistently showed an approximatelly five-fold higher
level of p53 protein expression in the revertants rather than Hela (Laser Densitometry of Western
Blots; average of four independent experiments). Remarkably, in the studies of Scheffner et al.
(1991), where HeLa cell p53 content was characterized as insignificant the quantitative
difference between p53 content in HeLa and a positive control cell line was only about five -fold
(relative values of 0.4 and 2). The HA and HF expressed levels of p53 that were intermediate
between those of positive control primary human fibroblasts (FS4) and HeLa cells. Figure 3
shows two immunoblots of p53 in HeLa, revertants and control cell lines indicating their relative
levels. Table 1.II summarizes the results of five independent experiments.
In conlusion, experiments that investigated the state of p53 in HeLa and revertant cells
using sensitive chemilluminescence detection methods showed that despite expression of E6 in all
three cell lines, p53 was expressed at detectable levels Although the fold- differences in p53
levels between HeLa and revertants varied cell culture confluence or nutrient availability, p53
expression was consistently found to be increased in revertants as compared to HeLa. It is
possible that increased p53 levels contribute to the revertant phenotype of both or one of the HA
and HF cell lines, possibly as a result of inactivation or inhibition of viral E6 oncoprotein
function.
p53 associates with cdc2-p34 in HeLa and revertants:
p53 has been previously reported to bind cdc2-p34 in tumor cell lines. Immunoblotting
with an anti-p34cdc2 antibody after purification of p53 complexes on an immunoaffinity column
is shown in Figure 6. p34cdc2 was readily detectable in association with p53 in HeLa, HA and
A431 cells, was detectable after prolonged exposure in HF cells (not shown) and was not seen in
negative control Saos-2 cells which do not express p53. Western blot analysis showed that HF
cells expressed greatly reduced levels of the p34cdc2 protein (data not shown). Could such a
reduction in p34-cdc2 explain the decrease in complexes in HF revertant cells. Even so, the
dramatic decrease in p53-cdc2 complexes would be expected to lead to greatly impaired
physiological function of this complex in the HF revertant.
The state of the Rb protein in HeLa and revertants
Like p53, Rb is a common target of DNA virus oncogenes namely the SV40 large T,
Adenovirus ElA and "high risk"-HPV E7 and its normal tumor suppressor functions are
abbrogated (Schmieg et al., 1984; Ludlow et al., 1989; Munger et al., 1989; Kaelin et al., 1990)
by preferential binding of these dominant viral oncogenes to underphosphorylated Rb. As
discussed in previous sections of this report, we reasoned that Rb activation may have contributed
to the revertant phenotype. It has been shown by others that the HPV-16 and -18 E7 proteins
decrease Rb levels in transfected human foreskin fibroblasts and epithelial cells (keratinocytes)
(Halbert et al., 1991). Thus we further considered the possiblty that E7 functional inactivation in
either revertant could lead to elevated Rb levels in this revertant as compared to HeLa. To
investigate the state of Rb in HeLa and revertants we carried out immunoprecipitation with the
monoclonal antibody 29C followed by immunoblotting with the monoclonal antibody IF8. We
detected no significant differences between the steady state levels of Rb protein in the three cell
lines (Figure 4a). Immunoprecipitation of metabolically labeled proteins (Figure 4b), however,
suggested that differences in the synthesis and the state of Rb phosphorylation may in fact exist
among the three cell lines. Specifically, increased levels of metabolically labeled Rb were
immunoprecipitated in HF cells as compared to HeLa. Furthermore, in both revertants, Rb protein
appeared as a doublet of well separated, distinct, phosphorylated and underphosphorylated
species, while in HeLa cells the predominant immunoprecipitated species was the
underphosphorylated Rb. Underphosphorylated Rb is preferentially bound by E7 (Dyson et al.,
1989; Munger et al., 1989; Imai et al., 1991; Munger et al., 1992), but there are no reports on the
effect of the E7-Rb interaction on Rb phosphorylation. If Rb-E7 binding interferes with Rb
phosphorylation, it is conceivable that the presence of differentially phosphorylated Rb species
could result from and be indicative of disrupted Rb-E7 binding and a consequent gain of Rb
function in the HF revertant. Alternatvey, differential Rb phosphorylation could be the result of a
mutation in Rb that allows the tumor supressor to escape inactivation by the E7 protein.
Alternatively, an E7 or Rb regulator i.e. casein kinase II (Firzlaff et al., 1989; Barbosa et al.,
1990; Firzlaff et al., 1991) or a cyclin/cdk complex (Taya et al., 1989; Thomas et al., 1991; Hinds
et al., 1992; Dowdy et al., 1993; Yen et al., 1994; Zhang et al., 1994) may have been the target of
the mutation(s) that generated the HF cell. Functional inactivation of E7 could explain the
apparent increase of metabolically labeled Rb in the HF revertant. The fact that the levels of Rb
appear similar in immunoprecipitation-immunoblotting experiments and vary in
immunoprecipitation from metabolically labeled cells, could be attributed to differences in cell
culture confluence or to differences in nutrient and growth factor availability. It is conceivable
that the distribution of each cell population -and hence its respective Rb content- varied between
experiments with respect to cell cycle stage. Rb phosphorylation could have also been a function
of the respective cell cycle distribution of each cell line.
During the course of unrelated experiments, we found that the differences in Rb
phosphorylation between HeLa and revertants were reversed by transient ectopic expression of
the adenoviral homologue of E7, the viral oncogene E1A (Figure 4b). E1A can thus change the
state of Rb expression and phosphorylation in the revertants to resemble that seen in the HeLa
cell. It would therefore be interesting to study whether Rb phosphorylation state and E1A
expression induce retransformation of either of the revertants. While E7 expression is known to
decrease Rb levels, E1A ectopic expression during transient transfection increased Rb in all three
cell lines. It is thus likely that there are fine significant differences between E1A and E7 function.
Thus the results obtained after transfection with E1A results may not be strictly indicative of E7
functional inactivation in either revertant.
The revertants differ from HeLa in terms of E2FI binding to Rb
Association between Rb and viral oncogenes prevents Rb binding to E2F a transcription
factor involved in control of cell proliferation (Sarnow et al., 1982; Bagchi et al., 1990; Pietenpol
et al., 1990; Chellappan et al., 1991; Nevins et al., 1991; Pietenpol et al., 1991; Hiebert et al.,
1992; Nevins, 1992; Nevins, 1992; Hiebert, 1993; Morris et al., 1993). Immunoprecipitation of
metabolically labeled Rb from HeLa and revertants suggested that differences in Rb
phosphorylation may exist between HeLa and revertants. Since phosphorylation regulates Rb-E2F
binding throughout the cell cycle (Chellappan et al., 1991; Chittenden et al., 1991; Helin et al.,
1992; Shirodkar et al., 1992) and is in general thought to play a pivotal role in the regulation of
Rb tumor suppressor functions (Mittnacht et al., 1991; Mittnacht et al., 1991; Cobrinik et al.,
1992; Hatakeyama et al., 1994; Mittnacht et al., 1994), I reasoned that differences in Rb
phosphorylation between HeLa and revertants may lead to corresponding differences in Rb-E2F
binding. I have thus carried out immunoprecipitation of E2FI containing complexes from Hela
and Hela revertant lysates with an anti-E2FI antibody, followed by immunoblotting with an anti-
Rb-antibody. This experiment revealed Rb-E2FI binding in the HF revertant and to a lesser extent
in the HA revertant. Such binding was not present in the HeLa cell (Figure 1.6a). Subsequent
incubation of the supernatant from the E2FI immunoprecipitation with anti-Rb antibody
immunoprecipitated unbound Rb from the HeLa lysate. A smaller amount of unbound Rb was
immunoprecipitated from the HA lysate (Figure 1.6b). Western blotting of nuclear extracts from
Hela, HF and HA showed that E2FI is expressed in Hela but was not detectable in the revertants
(data not shown). Taking into account the state of Rb in the three cell lines discussed earlier in
this report, the results shown in Figure 1.6 suggest that differential Rb regulation and/or E7
functional inactivation may have stabilized the physical interaction of Rb and E2FI. Rb-E2FI
association may in turn down-regulate the proliferative functions of E2F in the revertants.
Ectopic expression of viral oncogenes
The retroviral vector LXSN (a gift of D.A.Miller, FHCRC, Seattle) was used to generate
all of the viral oncogene transducing vectors. LXSN contains the Moloney Murine Leukemia
(MMLV) Virus Long Terminal Repeat (LTR) Promoter, a polylinker, the ampicillin resistance
gene and bacterial replication origin for expression in bacteria, and the neomycin gene under the
SV40 enhancer. Retroviral infection results to a single integration of provirus in each cell. Each
infected cell contains an integration,each integrated copy drives the expression of a G418
resistance gene as well as of the gene of interest. Hence while stable transfection requires the
cloning of single cells and characterization of individual clones, a pool of G418 resistant cells can
be used after retroviral infection and integration. Given the high copy number of HPV-18 DNA
integrated in the revertant genome, and the dominance of the revertant phenotype in HeLa x
revertant hybrids we did not expect that retroviral transduction of either or both HPV oncogenes
would affect the growth properties of the revertants in soft agar. Our results have been consistent
with this line of reasoning as shown in Table 1.IV. When revertants were infectedwith defective,
helper-free retroviruses that expressed high levels of the HPV-16 E6 , E7 or E6 and E7
oncogenes under the control of the strong promoter present in the Large Terminal Repeat (LTR)
(Halbert et al., 1991; Foster et al., 1993). Since the retroviral constructs also expressed the
bacterial neomycin resistance gene, we examined the phenotype of G418 resistant clones that
arose after infection. The morphology of the individual clones was indistinguishable from those
of the parental HA and HF revertants. We therefore tested pools of infected HA and HF cells for
their ability to grow in semi-solid medium (Table III). The results indicated that infection with
retroviruses expressing the E7 oncogene did increase the cloning efficieny of the HF revetant in
soft agar medium significantly, suggesting that decreased levels of functional pRB may contribute
to the revertant phenotype of this clone. In this experiment the cloning efficiency of the HA
clone was sunstantially higher than that observed in previous experiments. However. it should be
noted that the former experiments were performed several years earlier, thus suggesting that the
HA clone may have acquired a more aggressive in vitro growth phenotype during continuous
passage. Despite the observed effects of the E7 oncogene and enhanced cloning efficiency of the
HA clone, our results also demonstrated that ectopic overexpression the E6, E7 or E6/E7
oncogenes in the revertants failed to restore the transformed the in vitro phenotypes characteristic
of the parental HeLa cells. In contrast, expression of a superimmortalizing mutation of SV40
Large T in the HA revertant was able to retransform this cell line.

Discussion
Selection of non-transformed revertants based on loss of the rhodamine 123 has been
used successfully to isolate revertants from populations of oncogene transformed fibroblasts
(Zarbl et al., 1987; Maniatis et al., 1982). The present study describes the use of the same
selection procedure to isolate non-transformed revertants from HeLa cells that were derived from
a human cervical carcinoma. Initial phenotypic characterization of the revertants demonstrated
that these cells lost most of the in vitro properties associated with transformed cells, including a
transformed morphology, clonigenicity in semi-solid medium, and growth in suspension culture.
In these respects the revertants differ from HeLa x normal human fibroblasts hybrids, which,
although non-tumorigenic in nude mice, maintain the in vitro properties characteristic of the
parental HeLa cell (Maniatis et al., 1982; Srivatsan et al., 1986; Stanbridge et al., 1986).
However, the revertants isolated in our study also failed to form tumors in nude mice.
In order to rule out the possibility that the revertants represented contamination with other
cell lines, limited DNA fingerprinting of HeLa cell and revertant cell DNA was performed using
four variable number terminal repeat (VNTR) probes (data not shown). The fact that the
revertants were in fact derived from HeLa cells was further confirmed by Southern hybridization
analysis (data not shown) of the integrated HPV-18 sequences, which unequivocally
demonstrated that the three cell line had identical viral genome integration sites. The results of
this analysis further indicated that the integrated viral genomes remain intact in the revertants.
Northern hybridization analyses (data not shown) indicated that the HPV-18 specific transcripts
are expressed at the same level in the revertants as in the parental HeLa cells. The two major
transcripts identified by Northern hybridization correspond in size to mRNA species identified by
other researchers (Inagaki et al., 1988; Schwarz et al., 1985). The smaller 1.6 kb transcript was
shown to contain an alternatively spliced E6 gene and a full length E7 gene. The larger 3.4 kb
transcript was also polycistronic and encoded full length E6 and E7 genes and most but not all of
the El gene (Inagaki et al., 1988). The oncogenic potential of the HPVs has been attributed to the
E6 and E7 open reading frames (Dyson et al., 1989; Crook et al., 1991; Munger et al., 1989;
Werness et al., 1990). I have demonstrated that the levels of E6 and E7 proteins expressed in the
revertants are unchanged relative to the parental HeLa clone. Since HeLa cells contain multiple
copies of HPV-18 DNA integrated into their genome, it is not likely that mutational inactivation
of the E6 or E7 genes has lead to the revertant phenotype (Lazo et al., 1987; Schwarz et al., 1985)
This interpretation is consistent with our cell fusion experiments which indicate that the revertant
phenotype is dominant in HeLa x revertant hybrids and ectopic excression of the viral oncogenes
failed to retransform. Although we cannot formally rule out the presence of dominant negative
mutants of the E6 or E7 proteins, the involvement of such mutants in the reversion process is
unlikely, given the high copy number of the HPV-18 genome. It is thus more likely that the
revertant phenotype resulted from mutations that activate a suppressor of cell transformation.
Stanbridge and co-workers have demonstrated that suppression of tumorigenicity in HeLa X
fibroblast hybrid cells correlated with the presence of chromosome 11 and could be conferred to
HeLa by microinjection of the short arm of human chromosome 11. Zur Hausen an co-workers
have used Stanbridge's hybrids as well as hybrids between HeLa and immortalized rodent cells to
show that continued E6 and E7 function, are required for the maintenance of the transformed
phenotype (Bosch et al., 1990; Bosch et al., 1991). These hybrids continued to express E6 and E7
when grown in culture and grew in soft agar but mRNA levels of the viral oncogenes declined
two days after transplantation into nude mice and consequently failed to induce tumors. Zur
Hausen and coworkers have further shown that the suppression of Hela cells tumorigenicity in
athymic mice correlates with a dramatic decline of HPV E6 and E7 expression post-injection. The
fact that our revertants have lost the in vitro properties of transformed cells indicate that the
suppressor activated is probably not the chromosome 11 suppressor and that it may be able to
bypass the E6 and E7 functional pathways. Furthermore, all of the non-tumorigenic cell hybrids
generated from the fusion of HeLa cells and normal human fibroblasts invariably maintained the
in vitro characteristics of the transformed parental Hela . Thus, loss of the tumor suppressor gene
on chromosome 11 is likely to be associated with tumor progression rather than initiation of
carcinogenesis. In contrast, the events that led to reversion in our system may have affected early
pathways of transformation. It has been suggested that oncogenic HPVs are risk factors that
predispose cells to secondary events, including activation of a dominant oncogene and/or loss of
additional suppressor genes, necessary for progression of cells to a malignant phenotype
(Vousden et al., 1989; zur Hausen et al., 1989). In other words, the E6 and E7 functional
pathways contribute to the early events of carcinogenesis and in our system they may have been
affected during the reversion events despite the lack of evidence for mutation within the revertant
E6 an E7 genes. Changes in the association between one of the viral oncogenes and its respective
tumor suppressor or gain of function of either Rb or p53 would be the equivalent of partial or
complete interruption of E6 and E7 function. We thus studied the associations of E6 and E7 with
Rb and p53 as well as changes in Rb and p53 properties that would indicate gain of function in
the revertants.
Genetic alteration of p53 is the most common known event in human oncogenesis
(Levine, 1994). A vast volume of experimental data indicates that p53 functions as a negative
regulator of cell proliferation and its inactivation is necessary for the development of malignancy
(reviewed in (Zambetti et al., 1993), still the mechanism through which p53 functions as a tumor
suppressor remains obscure. Wild-type p53 has distinct DNA binding and transcription factor
properties (Kern et al., 1991; Kern et al., 1992; Zambetti et al., 1992). p53 expression is inducible
by DNA damaging agents such as Actinomycin D and y-irradiation and followed by the
transcriptional activation of genes involved in DNA repair such as gadd45 (Kastan et al., 1992;
Tishler et al., 1993). Overexpression of p53 results in G1 arrest (Kastan et al., 1992; Slichenmyer
et al., 1993) or apoptosis (Lowe et al., 1994; Lowe et al., 1993a; Lowe et al., 1993b; Lowe et al.,
1993c)and p53-transfection in p53 minus fibroblasts results in G1 arrest upon treatment with
DNA damaging agents (Nelson et al., 1994; Kastan et al., 1991; Sun et al., 1986; Lowe et al.,
1993). Taken together, these results support a model that p53 functions to prevent DNA
replication upon DNA damage until repair can occur, or induces apoptosis if repair or replication
fails (reviewed in Lane, 1993; Lane, 1992). Although selection against wild-type p53 concerns
the genotype of a very small fraction of cervical carcinoma, inactivation of the the tumor
suppressor protein by the "high risk" HPV E6 in all remaining tested cases has so far implicated
wild-type p53 function with one hundred percent of all the cervical carcinoma tumors and cell
lines examined (Scheffner et al., 1991; Crook et al., 1992a; Crook et al., 1992b; Crook et al.,
1991). The major mechanism of control of p53 expression appears to be through protein stability
(post-transcriptional modification; Oren et al 1981, Reich et al. 1981). Since HPV-16 and -18
could bind E6 in vitro and cervical carcinoma cell lines with HPV integrations carry the wild-
type p53 gene and express the p53 mRNA but show low levels of p53 protein, the hypothesis that
HPV E6 targets p53 for ubiquitination has been tested. HPV -16 and -18 E6 were thus found to
induce ATP and ubiquitin -dependent degradation of p53 in rabbit reticulocyte lysates (Scheffner
et al. ,1990) and a novel ubiquitin-dependent pathway has been implicated in p53 degradation
(Scheffner et al., 1992; Scheffner et al., 1992; Scheffner et al., 1993 ). In Hela cells, p53 mRNA
expression has been previously reported not to be inhibited but to be comparacle to that of
normal cells while the levels of the p53 protein were found to be undetectable (Matlashewski et
al., 1986) or very low (Scheffner et al., 1991). p53 cDNA sequence in our parental clone ATCC
CCL2 has been reported to be wild-type (Scheffner et al., 1991). p53 protein synthesis was,
however, shown to take place when p53 protein present was stabilized by transfection with a
mutant p53 and detected by immunoprecipitation (May et al., 1991). The result was consistent
with the hypothesis that p53 protein in the HeLa cell is targeted for rapid degradation by the
HPV-18 E6. Sensitive chemilluminescence detection used in immunoblots in combination with
high affinity primary and secondary antibodies gave us the ability to easily detect p53 in HeLa by
Western, or a combination of immunoaffinity purification and immunoblotting. When HA and
HF steady state p53 levels were compared to HeLa we found that p53 levels were increased 5-
fold in the revertants. Elevation of p53 levels in the revertants could have resulted from a
stabilizing mutation in the p53 gene. We believe, however, that this cannot be the case for both
revertants. Increased stability p53 mutants are usually gain of function mutants that actually
induce cell proliferation. In fact p53 was first identified in mutant form and characterized as an
oncogene. It is thus counterintuitive -though always possible- to assume that the p53 in the
revertants carries a stabilizing mutation. We are currently ruling out the possibility of p53
mutation using direct sequencing of p53 cDNA from HeLa and revertants and have data to
suggest that revertant express the wild-type p53 gene. Further study of our system could also be
helpful in identifying factors that are involved in p53-mediated G1 arrest or apoptosis.
Complex formation between p34cdc2 and p53 was seen in in Sv40 transformed mouse
cell lines (Milner et al., 1990 0. The same report showed that such interactions are specific for
wild-type p53. Other investigators have shown that p34cdc2 is a modulator of p53
phosphorylation both in vitro and in vivo and phosphorylation of p53 at the p34cdc2 site has been
found necessary for the ubiquitin-dependent degradation of the p53 protein (Lin and Desiderio,
1993). We are currently investigating whether increased p53 levels in the HF cell line, may result
from the lack of p53-p34cdc2 complex formation, and from a subsequent failure to target 53 for
degradation by phosphorylation at Ser-315. It remains unclear whether by binding p34cdc2 p53
can also regulate its function. The involvement of cdc2 in the reversion of the HF cell line is also
being investigated.
Immunoprecipitation of Rb from metabolically labeled cell extracts suggested different
rates of Rb synthesis and phosphorylation in the three cell lines. Specifically, Rb levels appeared
lower in HA than in HeLa or HF, Underphosphorylated Rb was the predominant Rb form in
HeLa while two distinct bands were present in HA and HF. We suspect differences in the Rb
phosphorylation potential of revertants and are currently investigating this hypothesis. Rb
changes in phosphorylation may account for the co-immunoprecipitation of Rb with E2FI from
revertant cell lystates that suggests Rb activation. The extent/dose of functional Rb activation
may be important to Rb contribuion in the reversion process as may be the interplay between Rb
and p53 gain of function in the revertants. E2F1-Rb association is transient in the cell cycle and
dependent on Rb phosphorylation by cell cycle regulatory complexes (Schwarz et al., 1993;
Shirodkar et al., 1992; Hiebert et al., 1993; Nevins et al., 1992). We are currently investigating
whether complex formation between Rb and E2F-1 could account for differential E2F-1 activity
in the revertants and what changes in Rb or E2F regulation can account for the restoration of
complex formation in HF. We are also testing the hypothesis that gain of function of Rb through
this complex may have contributed to the reversion (Hiebert et al., 1993).
Retroviral integration and ectopic expression of HPV-16 E6, E7 or a combination of the
two had no effect on the revertant phenotype suggesting that the reversion event has bypassed the
E6 and E7 functional pathways. Ectopic expression of SV40 Large T antigen, however, increased
the clonigenicity in soft agar of the HA but not the HF cell line by one hundred-fold. Hence SV40
large T possesses a biochemical function that can override the mechanisms responsible for
reversion in the HA, but not the HF cell line.
In conclusion, we have shown that protein-protein interactions in the pathway of p53
and/or Rb are affected in these two independent revertants of the HeLa cell line. The finding
provided evidence that change along the p53 with or without activation of the Rb pathway may
respectively be an obligatory and a necessary occurence for the reversion of cervical
transformation. These results corroborate functional studies which by retroviral transduction of
viral oncogenes suggest that the E6 and/ E7 pathways have been interrupted/bypassed during the
reversion process.
Table 1.I: Clonigenicity and Tumorigenicity of Revertants
Clonigenicity Tumorigenicity
Anchorage
Dependent
Clonigenicity in
vitro (%)
50%
5%
25%
Clonegenicity in
Semi-Solid
Medium (%)a
20%
0.01%
0.2%
Number cells
injected
1 X 107
1 X 107
1 X 107
Number of mice
with tumors
4/5
0/4
0/4
aGrowth in soft agar was performed in triplicate for each cell line tested. Exponentially growing
cells were removed from dishes by trypsinization and diluted with MEMN + 10% FBS. Aliquots
containing 104 cells, 103 cells or 102 cells were removed and seeded into molten Agar. The
number given is the average number of colonies formed per 100 viable cell seeded. Viability was
determined by seeding an identical dilution of cells onto standard tissue culture dishes.
Cell Line
HeLa
HA
HF
Table 1.II: Clonigenicity of Hela cells, HA and HF revetants and hybrid cells in soft agar.
Growth in soft agar was performed in triplicate for each cell line tested. Exponentially growing
cells were removed from dishes by trypsinization and diluted with MEMN + 10% FBS. Aliquots
containing 105 cells, 104 cells or 103 cells were removed and seeded into molten Agar in 30mm
dishes. Reduction of cells seeded by a factor of 10 resulted in reduction of colonies by about
between 50- and 100-fold.
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Figure 1.1: Morphology of Revertant Cell Lines and Growth Curves of Cell Lines Grown
in Suspension
(a) Top : Rounded and refractile morphology of the transformed parental HeLa cell line. Middle:
Flat, translucent, nontransformed appearance of revertant clone, HA. Bottom: Flat, translucent,
nontranformed appearance of revertant clone, HF. Magnification 40X; phase contrast optics.
(b) Cells in suspension cultures were grown in spinner flasks and incubated at 370 c in a 5% CO2
atmosphere on top of magnetic stir plates as described in Materials and Methods. Two identical
cultures for each cell line were grown in parallel. Plotted on the graph above is the average
number of cells per ml measured for each culture versus the number of days in culture.
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Figure 1.2 : The E6 and E7 protein levels are unchanged between Hela and revertants
(a) Immunoblot showing the 18KDa E6 species and a higher molecular weight species recognized
by the anti-HPV16/18-E6 monoclonal antibody CP15. E6 and associated proteins were
immunoprecipitated by anti-HPV18-E6 monoclonal antibody CIX1. 15% SDS-PA mini gel run
at 80V for 2hr. The HeLa lane is overloaded. When normalized for loading, the E6 in all three
cell lines is the same. The secondary antibody was horseradish-peroxidase-conjugated (Signal
Transduction Laboratories) and the ECL reagents (Amersham) were used for visualization of
bands.
(b) Immunoblot showing the 21KDa E7 species recognized by an anti-HPV18-E7 polyclonal
antibody (gift of Elizabeth Schwarz). E7 and associated proteins were immunoprecipitated by
anti-HPV18-E7 polyclonal antibody (gift of Denise Gallaway). 15% SDS-PA mini gel run at 80V
for 2hr.
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Figure 1.3: The state of p53 in HeLa and revertants.
(a) Western blot of p53 following immunoaffinity purification as described in Materials and
Methods. The secondary antibody was alkaline-phosphatase-conjugated (Santa Cruz
Biotechnology). No phosphatase inhibitors were used in this experiment. A 20cm X 20 cm 10%
Laemmli SDS-PAGE gel was run for 12hr at 40 C and 0.35Amp. BCNP/NBP tablets (Sigma)
were used as substrate for this experiment and the blot was washed with Tris.Cl, NaCl prior to
incubation with the enzyme substrate. In order for the signal from HeLa to be detectable we
loaded 3X more protein from HeLa than from revertant cell lines in this experiment.
(b) Western blot of p53 without immunoaffinity purification. The secondary antibody was
horseradish-peroxidase-conjugated (Signal Transduction Laboratories) and the ECL reagents
(Amersham) were used for visualization of p53. Phosphatase inhibitors were included in the
protein extraction buffer. 50Ctg of protein were loaded per lane on a 20 X 20 cm, 10% Laemmli
SDS-PA gel which was run overnight at 60 Cat 80V.
Table 1.II1: Relative levels of p53 protein in HeLa and revertants
Relative p53 protein levels
(w/ respect to HeLa)
1
5+3
5+3
13 + 10
0
Table III: Relative levels of p53 protein from Western immunoblots were quantitated by
scanning laser densitometry of linear film exposures using an LKB Laser densitometer. To obtain
the relative p53 levels readings for the intenity of the p53 bands from one autoradiogram were
divided by the corresponding value from the HeLa lane. The values presented here are averages
of five independent experiments for the HeLa, HA and HF and two independent experiments for
the FS4 and Saos-2 cells. No bands were detected in p53 negative control cells Saos-2and the
actula densitometer reading for the correponding lane was 0.
Cell line
HeLa
HA
HF
FS4
Saos-2
HeLa
I HA
HF
A431
Saos-2
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Figure 1.4: p53 associates with cdc2-p34 in HeLa and revertants:
(a) Western blot of p34cdc2 following a immunoaffinity purification of p53 and associated
proteins. A 15% mini Laemmli SDS-PA gel was run for 2hrs at 80V.
(b) Western blot of p34cdc2 from nuclear extracts of HeLa, revertants and control cells. A 12%
Laemmli SDS-PA gel was run for 2hr at 80V.
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Figure 1.5: The state of the Rb protein in HeLa and revertants
(a) Immunoblot showing Rb recognized by the anti-Rb IF8 monoclonal antibody. Rb and
associated proteins were immunoprecipitated by anti-Rb monoclonal antibody 29C1 (gift of Steve
Dowdy, M.I.T). 6% SDS-PA mini gel run at 80V for 2hr.
(b) Immunoprecipitation of Rb-1 from metabolically labeled cell extracts. HeLa, HA and HF cells
were either untransfected or transiently transfected with plAneo (E1A under the MMLV-LTR)
and harvested 24hrs after transfection. Saos-2 cells were used as a negative control and FS4 and
WI38 cells are two positive control cell lines. MAb29C1 immunoprecipitates both
phosphorylated and unphosphorylated forms of Rb. E1A protein levels were also higher in HA
than in HeLa and HF (as determined by immunoprecipitation, data not shown).
(c) Immunoblot showing the 21KDa E7species recognized by an anti-HPV18-E7 polyclonal
antibody in immunoprecipitates by either an anti-E7 or an anti-Rb antibody. E7 and associated
proteins were immunoprecipitated by anti-HPV18-E7 polyclonal antibody. Rb and associated
proteins were immunoprecipitated by anti-Rb monoclonal antibody C-36 (Oncogene Science;
anti-Rb-1 Ab-1). 10% SDS-PA 20 X20 gel run at 40C and 80V onernight.
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Figure 1.6: E2FI binding to Rb.
(a) Immunoblot showing Rb recognized by the by the anti-Rb IF8 monoclonal antibody in
immunoprecipitates with anti-E2F-I monoclonal antibody (Santa Cruz Biotechnology).
(b) Immunoblot showing Rb recognized by the anti-Rb IF8 monoclonal antibody. Rb and
associated proteins were immunoprecipitated by anti-Rb monoclonal antibody 29C 1, from lysates
that had been precleared with the anti-E2F-1 antibody as shown in (a).
Both (a) and (b)6% SDS-PA mini gel run at 80V for 2hr.
Table 1.IV. Soft Agar Cloning Efficiency of Revertants Expressing Ectopic HPV- 16 Oncogenes.
Cloning efficiency (%) a
60HeLa
HA + LXSN
HA + E6
HA + E7
HA + E6/E7
HA + SV40
HF + LXSN
HF + E6
HF + E7
HF + E6/E7
HF + SV40
a Exponentially growing HA and HF cells infected with LXSN retroviruses carrying the denoted
HPV-16 oncogenes or vector LXSN alone were harvested by trypsinization and diluted with
MEMN + 10% FBS. Aliquots containing 104 cells and 103 cells seeded into 0.3% molten agar
medium in 30mm dishes. Numbers shown are the averages of two independent experiments, each
performed in duplicate.
<3
<2
<2
<2
< 0.1
< 0.4
<1
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Abstract
We have isolated two non-transformed, non-tumorigenic revertants of the HeLa (ATCC
CCL2) cell line. Unlike the parental HeLa, the revertants have more than 100-fold lower cloning
efficiencies in semi-solid medium, and fail to induce subcutaneous tumors when injected into
nude mice. Continuous function of the E6 and E7 viral oncogenes of human papillomavirus has
been found necessary for the maintenance of the transformed phemotype in HeLa. We have
therefore tested for changes in the expression and function of these viral oncogenes. The main
function attributed to HPV E6 is inactivation of the p53 tumor suppressor protein mediated by
E6-p53 binding and the subsequent targeting of p53 for degradation. Thus HeLa cells express
very low levels of p53. Despite unchanged expression of the HPV-18 E6 mRNAand protein, both
revertants show increased p53 protein levels. Furthermore somatic cell fusion experiments
suggested that a dominant suppressor of transformation had been activated in both revertants. We
have been investigating whether functional activation of the p53 pathway has taken place in the
revertants and could contribute to the revertant phenotype.
We used retroviral transduction to ectopically express wild-type p53 in HeLa and to
examine whether p53 is sufficient for the suppression of the Hela phenotype. Ectopic expression
of the wild-type p53 was shown to decrease the clonigenicity of the Hela cell in soft agar by a
hundred fold. Mutation in the p53 gene of the revertants could explain the increased p53
expression in these cells but a mutant p53 would not be expected to contribute to the revertant
phenotype. RNAase protection assay and direct sequencing failed to detect mutation in the p53
cDNA's from HeLa and revertants. If the revertant p53 was shown to be functionally wild-type,
increased p53 protein levels in the revertants as compared to HeLa would be anticipated to
contribute to the revertant phenotype. We therefore tested revertant cells for the manifestation of
endogenous wild-type p53 function. As has been shown for the wild-type p53 gene in non-
transformed cervical cells, endogenous p53 in the revertants but not in Hela: i) is inducible by
treatment with Actinomycin D, an inhibitor of DNA synthesis, and by exposure to y-irradiation, a
DNA damaging agent, ii) possesses constitutive and inducible DNA binding properties and
promoter transactivating properties specific to the wild-type p53 gene. Furthermore, differential
expression of the endogenous gadd-45 and waf-lgenes -which are regulated transcriptionally by
p53- is observed between HeLa and revertants. An in vitro ubiquitination-degradation system was
used in order to investigate the causes of increased p53 protein in the revertants. Remarkably in
both revertant cell lines ubiquitin-dependent proteolysis of p53 was found to be impeded in
comparison to HeLa. Thus, functional activation of p53 in transcription as well as inhibition of
ubiquitin-dependent proteolysis correlate tightly with the reversion of transformation of cervical
carcinoma cells. E6-p53 complexes are detectable in Hela but not in the HA and HF revertant.
Inhibition of p53 degradation in the HF revertant may also be caused by interruption of complex
formation of p53 with p34cdc2. The lack and presence of this interaction in HF and HA
respectively may also explain the inability of SV40 Large T to retransform the former and its
ability to do so in the latter.
Introduction
Cervical carcinoma is the second most common gynaecological tumor and claims about
500,000 lives worldwide each year. As many as 90% of cervical carcinomas have been found to
contain integrated viral genomic sequences of Human Papilloma Viruses -16, -18, -31, -33 or -39
which have consequently been termed "high risk" HPV's (Durst et al., 1983), (zur Hausen, 1987)
,(zur Hausen, 1991), (Schiffman et al., 1991. In benign and premalignant lesions the HPV DNA
exists episomally, while in malignant lesions and cervical carcinoma cell lines HPV DNA is
integrated, often in multiple copies, with preservation of the E6 and E7 open reading frames and
disruption or deletion of the El and E2 genes (Schneider- Gadicke et al., 1988 ; Durst et al., 1987;
Popescu et al., 1989; Lazo et al., 1989 ; Sousa et al., 1990). In some cases, integration occurs in
the vicinity of oncogenes - usually c-myc - and leads to their increased expression (Schneider-
Gadicke, 1988). The E6 and E7 genes of the "high risk" HPVs have been implicated as essential
factors in cervical carcinogenesis because of their presence and expression in cervical carcinomas
and carcinoma cell lines (Baker et al., 1987, El Awady et al., 1987, Schneider-Gadicke and
Schwartz, 1986, Schwarz et al, 1985, Seedorf et all 1987, Smotkin and Wettstein, 1986,
Roggenbuck et al. 1991). Numerous studies have demonstrated the transforming properties of
these two viral proteins (reviewed in Mansur and Androphy, 1993). Most importantly , HPV-16
and -18 E6 and E7 can immortalize primary human keratinocytes (Kaur et al, 1988; Hawley-
Nelson etal.. 1989; Munger et al., 1989; Hudson et al., 1990; Barbosa et al., 1991; Halbert et al.,
1991; Schiller et al., 1989) and their maintained expression has been reported as both necessary
and sufficient for tumorigenicity and full blown transformation (Munger et al. 1989, Bosch et al.,
1990, Miyasaka et al., 1991). The transforming functions of the E6 and E7 are thought to result
from their respective binding and inactivation of the p53 and Rb tumor suppressor proteins
(Werness et al., 1990; Munger et al., 1989; Dyson et al., 1989).
The p53 tumor suppressor gene is the most commonly mutated gene in human cancers,
with seventy percent of all tumors and tumor cell lines examined carrying an altered p53 gene
sequence. Elevated wild-type p53 expression supresses the transformed phenotype of colon
carcinoma, osteosarcoma and breast carcinoma cell lines (Baker et al., 1990; Diller et al., 1990;
Mercer et al., 1990; Chen et al. 1991; Cheng et al., 1992; Wang et al., 1993). The exact
mechanism or mechanisms through which wild-type p53 functions in tumor/growth supression is
not known, although numerous studies have defined a role for p53 in response to DNA damage
(Kastan et al., 1991; Kuerbitz et al., 1992; Kessis et al., 1993; Lowe et al., 1993; Lowe et al.,
1994; Slebos et al., 1994), cell cycle control (Kastan et al., 1991; Perry et al., 1993; Slichenmyer
et al., 1993; Chen et al., 1994; Slebos et al., 1994), transcriptional activation (Kern et al., 1991;
Kern et al., 1991; Zambetti et al., 1991; Kern et al., 1992; Zambetti et al., 1992; Zambetti et al.,
1993) and DNA replication (Wang et al., 1989; Friedman et al., 1990; Bargonetti et al., 1991;
Bargonetti et al., 1992; Friedman et al., 1993; Reynisdottir et al., 1993; Wang et al., 1993; Moses
et al., 1994). A widely accepted hypothesis on p53 function is that whenever DNA damage
occurs, p53 protein levels become induced by a post-translational mechanism. The p53 induction
forces the offended cell to exit the cell cycle by inducing GI arrest or apoptosis. Thus when p53
function is unperturbed, cells that cannot replicate properly -because their DNA is damaged or
because of insufficient metabolites- either stop dividing or die and cannot develop into cancer
cells. Induction of p53 upon DNA damage is followed by p53-specific transcriptional activation
of genes involved in repair such as the gadd45 gene (Kastan et al., 1992) as well as genes
controlling the cell cycle, specifically the cyclin inhibitor cip-1/waf-1 (el Deiry et al., 1993).
Transcriptional activation and DNA binding are specific to wild-type p53 and not mutant p53
(Kern et al., 1991; Kern et al., 1991; Kern et al., 1992; ) and the induction of cip-1/waf-1 after y-
irradiation requires the presence of a functional p53 gene (Scott Lowe, personal communication;
el Deiry et al., 1993). Thus it is thought that the transcription factor properties of wild-type p53
are essential for its role in cell growth control.
The major mechanism of control of p53 expression appears to be through protein stability
(post-transcriptional modification; Oren et al 1981, Reich et al. 1981). Since HPV-16 and -18 E6
could bind p53 in vitro and cervical carcinoma cell lines with HPV integrations carry the wild-
type p53 gene and express the p53 mRNA but show low levels of p53 protein the hypothesis that
HPV E6 targets p53 for ubiquitination has been tested. HPV -16 and -18 E6 were thus found to
induce ATP and ubiquitin -dependent degradation of p53 in rabbit reticulocyte lysates (Scheffner
et al. ,1990) and a novel ubiquitin-dependent pathway has been implicated in p53 degradation
(Scheffner et al., 1992; Scheffneret al., 1992; Scheffner et al., 1993). Ubiquitin-dependent
degradation of p53 in vitro has been more recently shown to take place in the absence of E6
(Ciechanover et al., 1994). Wild-type p53 is a relatively short-lived protein with a half-life of
twenty minutes in non-transformed cells. Endogenous levels of p53 protein are low in certain cell
types and vary two - to four-fold between various stages of the cell cycle in p53 expressing cells.
It is therefore possible that ubiquitin dependent proteolysis is involved in the regulation of p53
protein expression in non-transformed cells and that E6 analogs may exist in such cells.
p53 has been implicated in one hundred percent of all the cervical carcinomas examined.
Ninety percent of carcinomas tested contain HPV integrations and express the E6 oncogene
which inactivates p53 by targeting it for degradation. All non-HPV cervical carcinoma cell lines
tested express a mutant p53 (Scheffner et al., 1991; Crook et al., 1992; Crook et al., 1992; Crook
et al., 1991). Deregulation of p53 function thus appears to be an absolute requirement for cervical
transformation.
In order to study cervical cell transformation we have employed an in vitro cell culture
system comprised of the cervical carcinoma cell line HeLa and two non-tumorigenic variants
(revertants), HA and HF. Such systems have been used succesfully to identify tumor the ras
suppressor gene k-revand transformation effector genes (Boylan et al., 1991; Kho et al., 1991),
whose products comprise and/or regulate the biochemical pathways of cellular transformation.
HeLa, is an epithelioid adenocarcinoma of the cervix and the first human cell line to become
established in culture. The parental clone, ATCC CCL2, used in our studies is the oldest available
freeze-down. The isolation and initial characterization of our two HeLa revertants, HA and HF
are described elsewhere (Athanassiou, M. et al, 1996a). Briefly,the revertant cell lines have been
selected for loss of prolonged rhodamine retention by fluorescence-activated cell sorting and for
morphology ; they have lost the ability to grow in suspension culture or in soft agar medium, as
well as the ability to form tumors in nude mice. The HeLa cells harbor approximately 10-20
copies of the high risk HPV-18 DNA per genome equivalent (Lazo et al., 1987; Lazo et al., 1989
Schwarz et al., 1985 ). These sequences are preserved in the revertants and all three cell lines
express comparable levels of the E7 and E6 viral oncogenes. Retroviral transduction and ectopic
expression of the E6 and/or E7 in the revertants has not restored the transformed phenotype thus
excluding the possibility that the revertant phenotype be an effect of an inactivating mutation p53
mRNA expression is not inhibited in HeLa cells but the levels of the p53 protein has been
reported as undetectable (Matlashewski et al., 1986)or very low while p53 cDNA sequence was
wild-type (Scheffner et al., 1991). p5 3 protein synthesis has been shown to take place by
transfection of a mutant mouse p53 and detection of endogenous wild type p53 by co-
immunoprecipitation of mouse-mutant/human-wild-type p53 complexes (May et al., 1991). In
our parental HeLa clone as well as in the revertants p53 mRNA is wild-type in sequence and p53
mRNA levels are comparable. Molecular characterization of HA and HF has established that the
reversion of transformation results from two distinct events albeit that increase of wild-type p53
protein levels appeared to be an obligatory occurence despite continued presence of the E6
oncoprotein. (Athanassiou et al; 1996a). We have hypothesized that the increase in wild-type p53
levels in the revertants as compared to HeLa may have resulted in the manifestation of wild-type
p53 functions and thus have caused/contributed to the revertant phenotype of either or both
revertant cell lines. In support of this hypothesis, we report in this paper that revertant but not
HeLa p53 displays constitutive and inducible transcription factor properties that are thought
essential for p53 function in cell growth control. Furthermore, retroviral transduction of the wild-
type p53 sequences in the HeLa cells is able to suppress anchorage independent cell growth at
least one hundred fold. Although we cannot yet conclude as to the extent of p53 contribution to
the revertant phenotype we have identified inhibition of p53 proteolysis as a cause for the
increased p53 levels in both revertants. Furthermore E6-p53 interactions necessary for the
ubiquitin-dependent degradation of p53 are interrupted in both revertants. Thus loss of E6
function is identified as the cause for differential p53 degradation and p53 activation in both
revertants. We have also observed interruption of p53-p34cdc2 complex formation in the HF
revertant and it is possible that lack of this interaction may be upstream of the loss of E6 function.
Materials and methods
Cell Culture:
HeLa CCL2, C4I, C4II, FS4 and Saos-2 cells were purchased from American Type Culture
Collection. A431 cells were kindly provided by the Laboratory of Robert Weinberg. C4I and C411
cells were grown in Waymouth's Medium supplemented with 10% fetal bovine serum (FBS).
FS4, A431, and Saos-2 cells were grown in DMEM with 10% FBS. HeLa and revertants were
grown in MEMN + 10% FBS or in MEMN +10% Nu Serum (Collaborative Research). Growth in
soft agar was assessed by seeding 1 X 102, 1 X10 3 and 1 X 104 cells in 2.5ml of MEMN
containing 10 % FBS and 0.3% molten Difco noble agar. Plates were incubated at 370 C in a 5%
C02 atmosphere. Plates were fed with 1.0 ml of 0.3% agar medium every 7-10 days. At the end
of 3 weeks colonies were stained with lml tetrazolium violet overnight, then inverted and dried
on 3MM Whatman paper. Colonies were counted from the plates with 103 cells plated.
Cells were grown to 70% confluence prior to continuous treatment with Actinomycin-D
(Sigma or Boehringer Manheim) or exposure to single y-irradiation at the doses 137 Cs y-Ray Cell
indicated in the figure legends. Cells were harvested at appropriate time points post-treatment as
noted.
Plasmids
The pG13 and pmG15 used in chloramphenicol acetyltransferase assays have been described in
Kern et al and were kindly provided by Dr. Bert Vogelstein. Briefly, both reporter constructs
contain the CAT reporter gene under the control of basal promoters with 13 repeats of the p53
consensus binding site and 15 repeats of a mutated consensus site respectively.
To generate plasmid pSP73-p53 -B/S a 1300bp BamHI/SmaI fragment containing the
entire wild-type p53 ORF DNA sequences was subcloned from pC53-SN3 (released by Dr. Bert
Vogelstein, Baltimore) into the pSP73 vector (Promega). The latter plasmid was used to generate
the RNA probe used in the RNAase protection assays. A plasmid from Ambion Inc., carrying a
proprietary mutant p53 sequence was used to generate a positive control RNA probe.
The BamHI inserts from plasmids pC53-SN3 and pC53-175 (released by Dr. Bert
Vogelstein, Baltimore) respectively contained the wild type p53 sequences and the codon 175
mutant sequences. They were subcloned into BamHI-linearized retroviral vector pLXSN and
resulting plasmids pLXSN-p53 and pLXSN-175p53 were used in the retroviral transduction
experiments.
Northern Blots
Cells were lysed in IM guanidine isothiocyanate and RNA was isolated by the acid phenol
method (Chomczynski and Sacchi, 1987). Aliquots of 20p.g of total mRNA were electrophoresed
through a 1.2% agarose gel containing 6% formaldehyde. The RNA was transfered to Hybond N
membrane (Amersham) electrophoretically in 25mM phosphate buffer pH6.5, at lAmp for 2hours
using the Bio Rad transblot apparatus and fixed by ultraviolet irradiation. Blots were hybridized
in 50% formamide, IM NaCl and 1% SDS for 30min then hybridized overnight at 420 C to
radiolabeled probes corresponding to either waf-1, gadd-45 or p53. Waf-1, 28SRNA and gadd-45
oligonucleotide probes were end-labeled with 3 2P-ATP (5000ci/mmol; NEN Dupont) using
polynucleotide kinase (BRL) by the random priming method. The gadd-45 probe was kindly
provided by A. Fornace. The waf-1 probe was an amplified cDNA fragment. An 1800bp p53
cDNA probe was labeled by nick translation using DNAase I/Pol (NEB). Membranes were
washed three times in 0.1M NaC1, 0.1% SDS at 650 C and autoradiography was performed using
an intensifying screen for the indicated times at -70oC. To control for loading and blotting
variations, gels were stained with ethidium bromide and photographed or membranes were
probed with an oligo corresponding to 28S ribosomal RNA or with the p53 probe.
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared as previously described (Dignam et al., 1983; Carrier et.al., 1992)
and used fresh or frozen in N2. DNA binding reactions were carried out for 20 min at room
temperature in a buffer containing 20mM HEPES (pH 7.9), 100mM KC1, 1mM EDTA, ImM
dithiothreitol, 0.5 gg of polydl.dC, 104 disintegrations per minute of labeled probe, 20% glycerol
and 12 gtg of nuclear protein extract. The probe used was a 20mer double stranded synthetic
oligonucleotide containing the consensus p53 binding sequence as reported by Funk et al. (1992).
Similar results were obtained when we used a 30mer double stranded oligo corresponding to
positions 1569-1598 of the human gadd45 gene (Kastan et al., 1992). Each oligo was labeled
separately with T4 polymucleotide kinase (New England Biolabs) using [y-3 2 P]ATP ,
5000ci/mmol (NEN, DUPONT) before the strands were allowed to reanneal. Where indicated
0.2 jg of monoclonal antibody 421 was added to the nuclear protein extract prior to its addition to
the binding reaction. The samples were then analyzed on a 4% nondenaturing polyacrylamide gel.
The consensus p53 probe used was the self annealing GGA CAT GCC CGG GCA TGT CC
oligonucleotide made by Ransom Hill Bioscience, Inc. Oligonucleotide was boiled then cooled
down to form a double strand. Labeled probe was purified on G25 or PAGE
cDNA sequencing
poly A+ mRNa from HeLa, HAand HF was isolated using the acid extraction method of
Chozminsky and Sacchi. Exons 4 to 11 were amplified by Reverse transcriptase PCR, using the
Ambion p53 mutation detection Kit. Multiple clones were subcloned into the plasmid pCR
specialized for the subcloning of PCR products and supplied by Stratagene. Both strands of
twelve cDNA clones from each of HeLa, HA and HF were subjected to sequencing and
compared to wild-type p53 sequences. No mutations were detected within the sequenced p53
region in any of the cell lines.
RNAase protection assay
An RNAase protection assay was used to compare relative levels of p53 in HeLa and
revertants as well as for the detection of mutations within the p53 cDNa sequences. Plasmid
pSP73-p53 -B/S was linearized with HindIII and a labeled antisense strand was synthesized from
the T7 RNAse polymerase promoter this probe was hybridized to 201gg of RNA extracted by the
acid guanidium extraction method (Chozminsky and Sacchi). The assay was performed using
Ambion's RNAase protection kit according to the manufacturer's protocol. A second probe,
synthesized from an Ambion Inc. proprietary plasmid and carrying a mutant p53 sequence was
used as a positive control for mutation detection. To detect the 1-actin transcripts, another probe,
synthesized from Hindll- linearized pBH-1 lwith T7 polymerase was used as an internal control.
Riboprobes were labeled with [a- 3 2P]UTP at 15Ci/mmol. 10lpg total RNA was hybridized with
wild-type or mutant p53 probe and with the 3-actin control probe in the same reaction tube after
incubation at 530 C for 15hr. The samples were digested with RNAase A and RNAase Tl and the
protected fragments separated in a 5% denaturing polyacrylamide gel and run at 200V for lhr.
The gel was then dried and exposed to Kodak X-AR film overnight.
CAT assays
Appoximately 5 x 106 cells were transiently transfected by electroporation with 10lpg pG13,
pmG15. As a control, cells subjected to the sane pulse in the absence of DNA. Electroporation
was carried out at room temperature in culture medium at 270mV/cm2 using a Bio-Rad Gene
Pulser apparatus. Twenty-four hours post-transfection, appropriate samples were treated with
0.45nM ActinomycinD for 4hrs or subjected to 600Rad of y-irradiation. Cell lysates were
prepared 48hrs post-transfection and a continuous enzymatic assay (Eastman, Biotechniques
1987) was carried out over a time course of 3hrs to quantitate chloramphenicol acetyltransferase
activity on tritiated acetyl-CoA. Linear curves of CAT activity over time were plotted and
relative CAT activity rates were calculated using the Cricket Graph software. Half of each cell
sample was used in a PCR based assay to normalize for transfection efficiency between samples
as previously described in Bahramian and Zarbl, 1994. Results from two independent
experiments were averaged and shown in Table 1.2.
Immunoaffinity purification of p53:
The p53 protein from HeLa, HA, HF, A431 and Saos-2 cells was purified on a mAb 1801 column
(p53 ImmunoCruz, Santa Cruz Biotechnology) according to the supplier's protocol. Cell lysates
were normalized for protein content prior to run through the column. The experiment was
repeated in three independent expeiments. The quantities of protein run through the column
ranged from 3-20mg in 2ml of lysate. The final eluate+Laemmli buffer volume was 600ml and
1/12 of that was used per electrophoresis run. When 20mg of lysate were used cell lysates were
first concentrated on Centriprep-3 columns (Amicon) prior to passage through the immunoaffinity
column. Immunoaffinity columns were also set up using 100.tl agarose conjugated mAb 240
(Santa Cruz Biotechnology). 2mg of protein extract was run through the mAb 240 column using
the same procedure as with the ImmunoCruz columns.
Western Blotting:
Protein samples were boiled in sample buffer for three minutes prior to loading on a Laemmli
gel. SDS-PAGE was carried out in Tris-Glycine buffer system (Harlow, #715) under constant
voltage of 80 V overnight using in either the Mini Protean (BIO-RAD) or a minigel apparatus
from CSB Scientific Co. for 2 hr, or at 150V on a Protean Apparatus (BIO-RAD). Protein
standards used were BIO-RAD low molecular weight prestained standards and BIO-RAD wide
range standards, which were visualized after transfer by treatment of the Western Blot with the
Aurodye Kit (Amersham) according to the manufacturer's protocol. Separated proteins were
transfered overnight on a PVDF membrane (Immobilon-P; Millipore). The transfer was
performed in the cold in the Trans Blotter apparatus (BIO-RAD) under constant voltage at 60 V
in transfer buffer (25mM Tris, 190mM glycine, 20% methanol). Upon completion of the transfer,
membranes were blocked in Blotto (5% milk in TBS-T) for 30min, then incubated with the
appropriate antibody dilution in Blotto for lhr 15min at room temperature. Blots were then
washed twice with TBS-T (pH 7.6; 20mM Tris, 137mM NaCl; 0.1% Tween 20) for 10min at
room temperature, incubated with a horseradish- peroxidase-conjugated anti-mouse or anti-rabbit
polyclonal secondary antibody (1:2000 dilution in Blotto; Santa Cruz Biotechnology or
Transduction Laboratories) for 30min. After being washed twice with TBS-T and once with TBS
(same as TBS-T without the Tween) or PBS. Proteins on the blots were detected with the ECL
reagents (Amersham) were used for antigen detection according to the manufacturer's protocol.
In order to check the quality of transfer and the loading of equal amounts of protein in each lane,
membranes were stripped in 0.2M ethanolamine at 820 C for two hours according to the
manufacturer's protocol, washed with PBS-0.4% Tween 20 and stained in 0.1% India ink in PBS-
0.3%Tween 20 (Harlow book as reference).
Retroviral transduction
Briefly, ecotropic helper-free virus was generated by transient transfection of the highly
transfectable BOSC cell line (60% transfection efficiency) using a highly efficient precipitation
with calcium phosphate method. High titer amphotropic split helper-free retrovirus was generated
by subsequent infection of the mouse ICRIP packaging cell line. Infectious TCRIP supernatant
was then incubated with HeLa and revertants for 24 hours. For all infections, infected cells were
selected in 500gig/ml G418. The pull of G418 resistant cells was tested for growth in soft agar and
molecularly characterized by Northern and Western analyses.
Antibodies:
Anti-HPV-18/E6 antibody C1X1 and anti-HPV16/18 antibody CP15 used respectively for E6
EMSA and Western blotting were purchased from Oncogene Science and Santa Cruz
Biotechnology. For the study of complex formation between p53 and other proteins we used the
ImmunoCruz system from Santa Cruz Biotechnology in which the column is loaded with
monoclonal antibody 1801. For Western blotting of p53 we used monoclonal antibody DO-1
from Santa Cruz Biotechnology. For p53 EMSA assays we used the monoclonals 421 and 1801
interchangeably (Oncogene Science; Ab-3 and Ab-1).
In vitro protein degradation assay
Cells were grown to 70% confluence in 150mm culture dishes. One plate per each cell line was
suspended in 20mM Tris. Cl (pH 8), 100mM NaC1, 1% NP-40, ImM DTT, 0.01% PMSF,
1lg/ml aprotinin, lLg/ml leupeptin, homogenized by passage through a Quiashredder (Quiagen).
The homogenates were then run through a pre-equilibrated cation exchange column (S-column ;
Bio-Rad) to partially purify the E6 activity or concentrated and desalted against ubiquitination
assay buffer on a Centricon 10 column. Proteins bound to the S-column were eluted with 500tl of
500mM NaCl, 20mM Tris.C1. The column eluate was then dialyzed against 500ml of
ubiquitination reaction buffer (25mM Tris. Cl pH7.5, 100mM NaCl, 3mM DTT) in a Slide-alyzer
(Pierce; molecular weight cut-off 10,000) for 2hrs at 40C. 35-S methionine-labeled or non-
radioactive wild-type p53 were generated in a coupled transcription-translation system (SP6 TNT
system; Promega) from a plasmid kindly provided by Jon Huibregtse in P. Howley' s laboratory.
2p1 of the in vitro translated radiolabeled p53 were incubated with 25p.g of the proteins eluted
from the cation exchange column or 2gl of a 1:5 dilution of unlabeled p53 were incubated with
50.tg of concentrated lysate in degradation reactions of total reaction volume of 40l.
Degradation reactions were carried out in ubiquitination reaction buffer with 6p1g ubiquitin and
2mM ATP or 2mM ATP-y-S. Control reactions were run in the presence or absence of rabbit
reticulocyte lysate. Reactions were ran for a time course of 3hrs at 300C. They were then stopped
with 20pl of 3X Laemmli buffer from New England Biolabs and subjected to 3min of boiling.
Half of each reaction was loaded on a 10% SDS-PAGE gel. For reactions containing radiolabeled
p53 the gels were dried out and exposed on a phosphorimager screen overnight. Gels of reactions
carried out with non-radiolabeled p53, were subjected to Western blotting with antibody DO-1.
The use of Western blotting with total protein extracts increased the sensitivity of detection and
allowed us the use of less p53 per reaction.
Results
p53 protein levels are increased in revertants as compared to HeLa
Previous reports found the levels of p53 protein in HeLa to be undetectable or negligible
(Matlashewski et al., 1986; Scheffner et al., 1991). We have reported that with higher sensitivity
Western blotting p53 is detectable in HeLa and was found to be at least five-fold increased in the
HA and the HF revertants relative to HeLa (Athanassiou et al, 1996a). While the levels of p53 in
all three cell lines varied depending on cell culture confluence and nutrient availability, p53
expression was consistently higher in the revertants than in HeLa.
p53 protein has been shown to be inducible in mouse fibroblast lines by treatment with
ultraviolet light or UV-mimetic drugs due in large part to increased stability of the protein. p53
induction has also been shown to take place in vivo in human skin subjected to UV. Similar
responses have been shown after treatment with y-irradiation or Actinomycin D. Exposure to
these inducing agents caused a temporary arrest in the G1 phase of the cell cycle expressing
wild-type p53, but not in cells with mutant p53. Furthermore, in malignant cells lacking
endogenous p53 the ability to arrest in GI after y-irradiation was partially restored when they
were transfected with a construct expressing wild-type p53. Overexpression of a mutant p53 in
tumor cells with a wild-type endogenous p53 abbrogated the GI arrest (Kuebritz et al., 1992).
Cells derived from patients suffering with Ataxia Telangiectasia -a disease characterized by
hypersensitivity to ionizing radiation, radioresistant DNA synthesis and a markedly increased
incidence of cancer- failed to induce p53 and in a manner very similar to that observed in p53
deficient cells and failed to arrest in Gl (Kastan et al., 1992). These results suggested that cell
cycle control requires the uninterrupted function of p53 inducing pathways. We have thus tested
the cell lines in our in vitro system formation for their ability to induce p53 protein levels after
treatment with relevant reagents such as Actinomycin D and y-irradiation. The relative ratio of
p53 in revertants vs. Hela was also found to increase upon y-irradiation and treatment with
actinomycin D (Figure 2). In the revertants,the rate of p53 induction was an order of magnitude
more rapid than in HeLa and resulted in ten fold higher p53 levels in the revertants (Table I). Our
results are comparable to the report by Kastan et al. (1992), who observed a seven-fold induction
of wild-type p53 in normal cells versus a two-fold increase in p53-induction-deficient AT cells.
These results suggested that the levels of the p53 protein in the revertants have been
restored to levels comparable to those of normal cells. Furthermore the p53 inducing pathways
essential to the function of p53 in cell cycle control are again functional in the revertants. We
were thus led to the hypothesis that elevated wild-type p53 expression could contribute or even
lead to the suppression of HeLa transformation in a manner analogous to data obtained for colon
carcinoma, osteosarcoma and breast carcinoma cell lines (Baker et al., 1990; Diller et al., 1990;
Mercer et al., 1990). We have thus undertaken to investigate whether or not and to what extent
p53 function contributes to the HA and HF revertant phenotypes.
The p53 gene has not been mutated in the revertants
Previous analysis of the p53 cDNA from the HeLa ATCC CCL2 clone showed that the
mRNA expressed in these cells encodes wild-type p53 (Scheffner et al., 1991). Both
immunoprecipitation and combination of immunoprecipitation and immunoblotting studies have
shown that the p53 protein in these cells was much lower when compared to protein in other cell
lines with comparable mRNA expression levels (Matlashewski et al., 1986; Scheffner et al.,
1991). Mutations within a p53 allele have been shown to increase the p53 half-life and may
therefore account for increased levels of p53 protein in the revertants. It is conceivable that
revertants harbored p53 mutations that resulted in stabilization of p53, while maintaining some of
its tumor suppressing properties. However, all of the mutations identified to date that affect p53
stability also so far identified p53 mutations lead to loss of growth-suppressor or gain of growth-
promoting function (Bargonetti et al., 1991; Kern et al., 1991; Kern et al., 1991; Zambetti et al.,
1991; Bargonetti et al., 1992; Bargonetti et al., 1992; Farmer et al., 1992; Zambetti et al., 1992;
Zambetti et al., 1993; Olson et al., 1994). Nonetheless, there remained a possibility that a
mutation occured in the p53 gene and that the mutation prevented degradation without affecting
function.
Therefore, we have employed RNAase protection assay and direct sequencing of cDNA
to test whether HeLa and either or both of our revertants have suffered a mutation within the p53
gene. Hybridization of endogenous mRNA from all three cell lines with probes scanning the
entire p53 ORF protected the entire probe from digestion with RNAase A and T1, while
hybridization of the same probe with in vitro transcribed mutant p53 mRNA resulted in cleavage
of the mismatch hybrid species and generated two bands on denaturing PAGE. Although this
approach is fast and less laborious than direct cDNA sequencing, it has the disadvantage that it
can only detect one third of point mutations due to the inability of the RNAase to detect
mismatches. We have thus sequenced revertant and HeLa p53 coding sequences that correspond
to the regulatory and DNA binding regions of the p53 protein, specifically exons 4 to 11. Exons 5
to 8 have been shown to contain more than 90% of the mutations observed in human tumors. We
have detected no mutations within the sequenced regions in any of our three cell lines of study.
The detection of p53 in many studies has relied on the use of a panel of monclonal
antibodies that recognize different epitopes of the murine and human p53 proteins (Harlow et al.,
1981; Yewdell et al., 1986; Gannon et al. 1990, Cook and Lane, 1990). The wild-type p53 protein
can assume two conformations during the progression of the cell cycle, where each of which may
play a distinct role in the physiological life of the cell (Ullrich, et al., 1992). One conformation is
specific to the wild-type protein and has been associated with the ability to block cell cycle
progression. The other conformation seems to function in promoting cell proliferation and was
originally identified as a characteristic distinguishing mutant p53 from wild-type. The mutant
latter conformation is recognized by antibody 240. As further evidence that no mutation has
occured within the p53 gene in our HeLa and revertants we attempted to purify cellular p53 from
the three cell lines on immunoaffinity columns loaded with monoclonal antibody 240 that
recognizes mutant p53. No mutant p53-specific signal was detected on immunoblots of the
eluates from these columns (data not shown), consistent with the absence of mutant p53 in the
revertants.
p53 specific endogenous transactivating activity is detectable in the revertants and inducible by
Actinomycin D and y-irradiation.
p53 was found to transactivate mammalian genes such as the muscle creatine kinase
(Weintraub et al., 1993).and subsequently shown to bind DNA both specifically (Kern et al.,
1991; Bargonetti et al., 1991) and non-specifically (Steinmeyer et al., 1988; Kern et al., b, 1991).
When the p53 response element was included in basal promoters and placed 5' of the CAT
reporter gene, the reporter was transactivated when co-transfected with wild-type p53 (Zambetti
et al,1992; Kern et al., 1992; Farmer et al., 1992). Furthermore when mutant and wild-type p53
were co-expressed there was a dominant effect of the mutant p53 that was related to decreased
binding of presumed wild-type mutant oligomers to DNA (Kern et al. 1992). The pG13-CAT and
pMG-15 CAT reporter constructs have been previously described (Kern et al., 1992). They
contain the polyoma virus early promoter and the CAT respectively downstream of 13 wild-type
and 15 mutated repeats of a p53 binding sequence.
Differential activation of the p53 reporter construct pG13CAT without and upon transient
treatment with Actinomycin D or exposure to y-irradiation was assessed in Hela and revertants.
Transfection of cells was performed by electroporation, Cells were harvested after 24 post
transfection and CAT assays were carried out as described in Neumann (1987) with a
modification by Eastman (1987). The technique is a continuous assay and thus yields quantitative
kinetic data that can be analyzed by standard mathematical means. Data from the CAT assay were
normalized for the relative transfection efficiency of the cell lines as described in Bahramian and
Zarbl (1994). Briefly, we employed a PCR based technique to directly quantitate the relative
amount of transfected DNA within the nucleus rather than using a second reporter gene to
normalize CAT activities. We thus eliminated variability across cell lines in the control of
expression of the second reporter gene. The results of three experiments are summarized in Table
2.2. Activities reflect the rate of conversion of chloramphenicol to an acetylated form, expressed
relative to the corresponding rate in the untreated HeLa cells. Activities of the control pMG15
were below the level of detection in all three cell lines with or without treatment. Thus, any
differences observed in transactivation of pG13 across cell lines are due to the presence of the
p53 binding sequences rather than of any element in the polyoma early promoter. That the levels
of p53 transactivational activity were sufficient to detect in uninduced cells that naturally
expressed p53 was surprising since in most previous work, the CAT reporrter constructs were co-
transfected with wild-type p53 expresssion vectors. Transient transfections would yield much
higher levels of the exogenous p53 than expected to be endogenous in a cell. Among untreated
cells HF showed the highest levels of p53 transactivating activity with a relative CAT rate of 30.
The activity in this cell line, was not significantly increased by treatment with Actinomycin D and
was only slightly increased by y-irradiation. CAT activity in untreated HA was twenty-fold higher
than in HeLa. Transient treatment with Actinomycin D and exposure to y-irradiation both
increased the relative CAT rates two-fold compared to untreated HA thus up to fifty-fold with
respect to HeLa. These results clearly display that p53 specific transactivational activity
constitutively elevated in revertant cells but not in HeLa , consistent with our hypothezis that the
p53 protein in the revertants is not only increased as compared to HeLa but also functional. The
levels of p53 specific transctivational activity are constitutively high in uninduced cells. The
observed increase in p53 function after y-irradiation or ActD (2-fold) was not as dramatic as the
observed (10-fold) increase in protein levels. These results are however in agreement with the
findings of Zhan et al. (1993) who did not observe significant increases of pG13-CAT
transactivation after transient transfection and treatment with 5Gy of ionizing radiation of RKO
cells which carry wild-type p53 that is able to induce and G1 that is able to arrest following
ionizing radiation. Therefore, our results indicate that the revertants express elevated levels of
wild-type p53.
p53-specific DNA binding is inducible in the revertants but not in HeLa - EMSA
As a further test of the gain of function of endogenous p53 in revertants as compared to
HeLa we carried out gel mobility shift assays using the consensus binding sequence or a
sequence from the 3d intron of the gadd 45 gene (Figure 2.3). Upon incubation of p53 specific
antibody with the labed double stranded oligonucleotide and the nuclear extracts, a distinct band
with a shifted mobility was seen in treated revertants and positive control FS4 cell extract. The
shifted band was not visible in the absence of incubation with the 421 antibody in induced
revertant cell extracts and was blocked with addition of excess 100-times excess of unlabeled
oligomer. Nuclear extracts were tested for the presence and induction of p53 by Western blotting.
These results demonstrate that an inducible factor that contains p53 can bind p53 binding sites in
the revertants but not in HeLa cells.
Constitutive expression of gadd45, inducible expression of waf-l in the revertants but not HeLa
Damage to DNA in both prokaryotic and eukaryotic cells lead to transient delays of cell
cycle progression by blocking the passage from the G1 phase to S and from the G2 phase to M
which presumably respectively prevent replication of damaged DNA and segregation of damaged
chromosomes. Until p53 was implicated in Gl arrest following y-irradiation (Kastan et al., 1991)
little was known about the mechanism that led to the cell cycle arrest following DNA damage.
Kastan et al., (1992) showed that in Ataxia Telangiectasia cells which failed to arrest in G1 much
like in p53 defficient cells, p53 protein induction failed following y-irradiation as did the
induction of the mRNA of the growth arrest and DNA damage inducible gene gadd-45. The same
authors correlated the lack of gadd45-mRNA induction with lack of p53 binding to a binding
site within intron 3 of the gadd45 gene. Zhan et al. (1993) provided further evidence suggesting
that p53 involvement in gadd45 induction is specific to y-irradiation and not other treatments. We
have therefore tested the state of the gadd45 mRNA in our HeLa and HeLa revertants by
Northern hybridization. The results (Figure 2.4). Demonstrated that the levels of Gadd45 mRNA
were at least 10-fold lower in HeLa than in revertants, without prior treatment of cells with y-
irradiation. Although we did not find the gadd45 mRNA levels in the revertants to be induced by
y-irradiation ,the fold difference in HeLa and revertant gadd45 mRNA is equal to the maximal
induction reported for any cell line (RKO cells; Kastan et a., 1992). Given that HA and HF are
both clones of HeLa we could consider gadd45 levels already maximally induced with respect to
HeLa gadd45 mRNA levels. Furthermore, the fact that gadd45 expression is constitutive is in
agreement with the CAT assay data that detect p53 specific transactivating activity even in
unstimulated cells. Finally, p53 specific binding of the gadd45 binding site is detectable in the
revertants but not in HeLa and appears inducible in at least the HA revertant. It remains possible,
however, that despite a functional p53 in the revertants, the y-irradiation-dependent pathway of
gadd45 induction may be interrupted by mutation of some factor necessary for p53 mediated
gaddd45 DNA binding and gaddd45 mRNA induction. It is conceivable that such a factor may
have been mutated during the trasformation of the HeLa cell.
The WAF-1 gene was first identified by its differential induction by wild-type p53, but
not mutant p53. The induction is thought to be mediated by direct transactivation of the waf-1
promoter by p53, since the identified p53 binding sites within this promoter can confer p53
specificity to reporter constructs (El Deiry et al., 1993). WAF-1 was then found to be identical to
a gene called CIP-1 which encoded an inhibitor of cyclin/cyclin kinase complexes (Harper et al.,
1993). A connection was thus established between p53 and cell cycle control, and evidence has
since been accumulating to support the hypothesis that induction of p53 under conditions of
cellular stress or DNA damage leads to inhibitiion of cell cycle progression through the waf-
1/cip-1 protein. All current evidence suggests that wild-type p53 function is absolutely essential
to waf-1 induction (El Deiry et al., 1993). As a further test for the restoration of wild-type p53
function in our HeLa revertants, we have assessed the state and inducibility of wafl mRNA. The
indicated that waf-1 mRNA is inducible by y-irradiation in the revertants, but not at all in HeLa
cells.
Taken together results results from CAT assays, DNA binding and expression of
downstream p53 effectors established that both revertants not only show increased levels of p53,
but have gained wild-type p53 function. Therefore, we have detected a very tight correlation
between activation of p53 function and suppression of the malignant phenotype in 2 independent
revertants of HeLa cells.
Wild-type p53 can suppress HeLa transformation
Having thus established that wild-type p53 function had been restored to the revertant clones
during the reversion process, we wished to determine whether wild-type p53 function alone was
sufficient to suppress the HeLa transformation. p53 inactivation by E6 is thought to be an
initiating step of cervical carcinogenesis and hence of Hela transformation. Although
inactivation of p53 is thought to contribute to the genomic instability that is further thought to
promote oncogenic/transforming mutations required for the malignancy of tumors, re-
introduction of p53 suffices to supress the transformed phenotype in many tumors, independent of
the presence of such secondary mutations. Moreover, previous results have shown that
decreasing E6 activity by Antisense RNA can inhibit transformation of HeLa, presumably by
increasing p53. Therefore, we expected that reinroduction of p53 in the HeLa cells would
suppress transformation, provided that exogenous p53 would exceed the saturation point of the
E6 pathway that targets p53 for degradation in the HeLa cells. We have employed retroviral
transduction to introduce p53 in the HeLa cells. The retroviral vector, LXSN, into which the
wild-type p53 sequences were cloned, is a widely acceptable vector that also drives the
expression of the neomycin resistance gene in infected cells. Thus succesfully infected cells gave
rise to G418 resistant clones that expressed exogenous p53, as verified by Northern blotting in
which it was possible to distinguish the exogenous RNA of 1800b from the 2400b -long
endogenous HeLa mRNA (data not shown). The pool of Hela cells expressing exogenous p53
(HeLa-p53) was compared to HeLa by soft agar growth assay. Clonigenicity in soft agar was
thus shown to be reduced 100-fold by introduction of exogenous p5 3 into the HeLa cells. Western
blotting analysis showed that the levels of p53 protein in Hela-p53 are not as high as revertant
p53 levels. This finding was consistent with the obsevation that growth of the revertants in soft
agar is even more reduced when compared to HeLa-p53 pool. Our previous results demonstrated
retroviral transduction of E6 does not have an effect on the revertant phenotype, suggesting that
the E6 functional pathway is interrupted/inhibited in the revertants. That would not be the case for
Hela p53 where endogenous E6 would still antagonize exogenous p53 expression. In any case,
retroviral transduction of p53 into HeLa suppressed transformation to a significant extend and
suggested that gain of p53 function could suffice to revert Hela cells from tumorigenicity.
Disruption of p53 Function in HeLa Revertants.
We so attempted to interrupt wild-type p53 function in the revertants through retroviral
transduction in the revertants of an exogenous dominant mutant p53, the His to Arg 175 mutant.
Previous work has shown that p53 is functional in tetrameric complexes (Friedman et al., 1993).
As previously mentioned, wild-type p53 can exist in different conformations, one of which is
unique to the wild-type protein and termed the wild-type conformation while mutant p53 is
"trapped" in the so-called mutant conformation. Milner and coworkers have demonstrated that
when mutant and wild-type p53 are co-expressed in vitro (1:1 molecular ratio) the wild-type p53
polypeptides were forced into the mutant conformation. Furthermore Kern et al. showed that
transiently transfected 175 mutant could reduce the p53 transactivation of reporter constructs
inthe presence of cotransfected wild-type p53. We reasoned that if the same effect would occur
in vivo, then ectopic expression of the mutant p53 would drive the formation of inactive dimers
and tetramers with endogenous wild-type p53. This would decrease wild-type p53. Thus,
expression of a dominant negative mutant in a revertant that has been generated through p53
activation would conceivably retransform this revertant. However, retroviral transduction of the
175 mutant did not result to increased clonigenicity of the reveratnts in soft agar although we did
observe a slight increase in the size of soft agar colonies in the HA cell line expressing the mutant
p53.
In retrospect, the failure of dominant negative mutant was expected if endogenous p53 in
the revertants had gained wild-type p53 function. First, suppression of anchorage independent
growth in soft agar or of tumorigenicity in nude mice by ectopic expression of wild-type p53
occur in the tumors examined irrespective of whether they tumors express mutant p53. Second,
no tumor has been described that carries simultaneously a mutant and a functional wild-type p53
gene. Third, Ullrich et al., showed that in a human glioblastoma cell line containing endogenous
mutant p53 ectopic expression of inducible wild-type p53 gene, both wild-type/wild-type and
wild-type mutant complexes exist. In these cells, the wild-type p53 can exert its antiproliferative
effect and upon GI arrest there are no wild-type/mutant complexes in the cell. Thus, the allosteric
effect of mutant p53 may not occur in vivo in the same dirrect manner as in vitro. Finally, in
Saos-2 cells which lack endogenous p53, simultaneous retroviral transfer and expression of the wt
and a dominant mutant p53 genes was able to suppress anchorage independent growth and
tumorigenicity much as expression of wild-type alone (Chen et al., 1990). Similarly, Wang et al.,
(1993) have reported that retroviral gene transfer can suppress the growth of MDA-MB468 a
breast carcinoma cell line overexpressing mutant p53. Thus, in the in vivo contexts examined,
wild-type p53 has a dominant effect over the mutants biochemically defined as dominant. Results
from the retroviral transfer and expression of the 175 mutant in the revertants taken together with
the manifestation of endogenous p53 function in the revertants are therefore consistent with a
dominance of wild-type p53 function in vivo in the context of the revertant cells.
Inhibition of p53 Degradation in the Revertants
In order to define the mechanism underlying increasing p53 in revertants, we first
considered E6 function, since functional inactivation of E6 in either revertant would ultimately
lead to lack/reduction of p53 ubiquitination and degradation. It was also conceivable that
interruption of p53 ubiquitination or degradation could occur independent of E6 function. We
have thus performed in vitro experiments after Scheffner et al. (Scheffner et al., 1990) to test
whether in vitro translated p53 is differentially degraded in HeLa and revertant lysates. Figure 2.5
shows the results of two independent experiments, the first one of which was carried out after
partial purification of basic proteins to concentrate HeLa and revertant E6 protein. The remaining
components of the ubiquitin-dependent degradation pathway, including the ubiquitin ligase E6-
AP are provided from the rabbit reticulocyte lysate added in the degradation reactions. The results
of this experiment showed that p53 degradation is faster in the presence of a basic protein
function from Hela than from revertants, thus suggesting inactivation of E6 mediated proteolysis
of p53 in the revertants. The degradation of ubiquitinated p53, but not the ubiquitination itself,
can be blocked by ATP-y-S. Thus addition of ATP-y-S to the degradation reaction mixtures
would allow the formation and recognition of high molecular weight ubiquitinated intermediates.
In cellular extracts of all three cell lines, HeLa, HA and HF, ATP-y-S inhibited p53 proteolysis
to the same extent demonstrating that the differential degradation of p53 in the revertants is due to
aberration of the ubiquitin dependent pathway rather than a general proteolytic pathway.
Furthermore, after addition of ATP-y-S, bands of higher molecular weight than p53 but lower
than would be expected for fully multi-ubiquitinated species are seen in revertant sample lanes.
The second experiment presented in Figure 2 5 was carried out using total cell lysate in the
degradation reactions. In order to increased the specificity of detection, in this second experiment
we decreased the amount of in vitro translated p53 in each degradation reaction by four-fold and
used Western blotting to visualize the fraction of p53 protein remaining upon a 3hr incubation
with cellular extracts. As in the previous experiment degradation reactions contained reticulocyte
lysate to enrich for the components downstream of p53-E6 binding. Under the conditions
described and in the absence of ATP-y-S, significant proteolytic degradation of p53 was observed
in HeLa, HA and control reactions with reticulocyte lysate. p53 proteolysis has been shown to
take place in reticulocyte lysates in the absence of E6 (Ciechanover et al., 1994) and the vast
excess of the reticulocyte lysate proteolytic components may be masking the differences between
HeLa and the HA revertant. On the other hand, degradation of p53 in the HF revertant lysates
appeared to be altogether inhibited suggesting that an inhibitor of p53 proteolysis is active in this
revertant. Again a band of higher molecular weight than the in vitro translated p53 was
specifically seen in reactions containing HF revertant lysates even in the absence of ATP-y-S and
in both revertant lysates in the presence of ATP-y-S. We shall call this band, band A. Direct
immunoblotting of samples from both experiments described in this section, with anti-ubiquitin
antibodies recognized a band that could be superimiposed with band A from identical gel runs.
However, since reticulocyte lysate were included in the degradation reactions, a multitude of
ubiquitinated species were recognized by the anti-ubiquitin antibody. The resulting high
background in the Western detection has thus precluded the identification of any ubiquitinated
species as conjugates of p53 without prior immunoaffinity purification of p53 species.
Taken together, results from both experiments suggest that differential degradation of p53
may be the cause of p53 accumulation in both revertants. Our data suggests the presence of an
inhibitor of p53 degradation in the HF revertant. Future experiments will dissect in greater detail
the ubiquitination-degradation pathways in HeLa and revertants and will aim at identifying the
cause of differential p53 degradation in these three cell lines.
Interruption of E6-p53 binding in the revertants
A combination of immunoaffinity purification of p53 and complexed proteins and
immunoblotting was used as a very sensitive assay that enabled us to study the association of p53
and E6. We found that E6-p53 binding has been disrupted in the revertants. Such disruption could
account for the increased levels and gain of function of p53 in HA and HF and could have
resulted: i) from changes in the post-translational modification of E6 or p53; ii) from abberant
expression of E6-AP, the 100KDa protein that participates in a quaternaty complex formation
with p53, induces E6-p53 binding and functions as a ubiquitin ligase (Huibregtse et al., 1991;
Scheffner et al, 1993); iii) from mutation of the p53 gene (Scheffneret al., 1992). These results
provide veidence for the interruption of E6 function in the revertants andcan explain the previous
finding about differential degradation of p53 in HeLa and revertants as well as the increase in p53
protein levels in the revertants.
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Figure 2.1: Differential p53 induction by ActD between HeLa and revertants.
Western blot of p53 using monoclonal antibody DO-1, on 50pg of total cell lysate of HeLa, HA,
HF and control cell lines. Cells were induced with 0.045nM of Actinomycin D for 0, 12, 24 and
48hrs prior to cell lysis. Cell lysis was carried out in boiling lysis buffer (10mM Tris, 1% SDS)
and cell lysate was homogenized by passage through a 23 gauge needle. Protein quantitation by
the Pierce BCA kit was carried out prior to addition of 2X Laemmli sample buffer. 50pg of
protein were loaded per lane of a 20cm X 20 cm 8% Laemmli SDS-PA gel. Gel Electrophoresis
was carried out under constant current of 0.35Amp, at 40 C, for 12hr. Relative p53 levels were
quantitated by scanning laser densitometry using an LKB Laser densitometer.
Table 2. I: Kinetics of p53 induction in response to Actinomycin D in HeLa and revertants
Cell Line Rate of p53 induction Relative Rate Curve Fit (R^2)
HeLa 0.083 1 0.254
HA 1.542 18 0.998
HF 1.053 13 0.953
FS4 5.500 66 1.000
Table 2.1: Relative levels of p53 protein as determined by Western blotting using monoclonal
antibody DO-1 according to the protocol described in Figure 1. Cells were induced with 0.45nM
of Actinomycin D for 0, 12, 24 and 48hrs prior to cell lysis. 50mg of protein were loaded per lane
of a 20cm X 20 cm 8% Laemmli SDS-PA gel. p53 levels were quantitated by scanning laser
densitometry of linear films exposures using an LKB Laser densitometer as described in the
legend of Table II. No p53 was detected in p53 negative control cells Saos-2. Curves of p53
induction, rates and curve fits were obtained using the program Cricket Graph,. Relative Rates
were obtained with reference to the HeLa cell line. p53 is induced by ActD in revertants at a 10-
to 20- fold higher rate than in HeLa. p53-mediated response to ActD treatment is thus faster and
yields higher levels of p53 protein in the revertants than in HeLa cells.
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Figure 2.2: Induction of p53 by y-irradiation in HeLa and revertants.
Western blot on 25p.g of total protein from cells dosed with 0, 3 or 6 Gray of y-irradiation four
hours prior to preparation of cell extracts. The primary antibody was horseradish peroxidase-
conjugated DO-1 (Santa Cruz Biotechnology). Cell lysis was carried out in boiling lysis buffer
(10mM Tris, 1% SDS) and cell lysate was homogenized by passage through a 23 gauge needle.
Protein quantitation by the Bio-Rad AB kit was carried out prior to addition of 2X Laemmli
sample buffer. A 10% Laemmli SDS-PA mini-gel was run. Relative p53 levels were quantitated
by scanning laser densitometry using an LKB Laser densitometer. H = Hela, A = HA, F = HF.
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Figure 2.3: Differential DNA binding by p53 between HeLa and revertants.
Cells were treated with 0.45nM Actinomycin D for 4hrs prior to preparation of nuclear extracts as
previously described (REF). Electrophoretic mobility shift assays were carried out with a 32 P-end
labeled oligonucleotide that contained a single repeat of the consensus p53 binding site as
previously described (REF). Induction of p53 was verified by Western blotting on 15p.g of
nuclear extract. p53 bound oligo was supershifted by the monoclonal antibody 421 (Oncogene
Science; Ab-1). 100x=competition with 100-times molar excess of unlabeled oligo, u = untreated
cell extract, t = cells treated with Actinomycin D, no Ab = no antibody. FS4 are positive control
normal fibroblast cells. Similar results were obtained with an oligonucleotide from the gadd45
gene (Kastan et al. 1992). Induction of p53 protein by actinomycin D treatment is followed by
increased binding of p53 to its consensus DNA sequence in the revertants but not in Hela.
Binding to the consensus sequence is characteristic of wild-type p53. The data thus supports the
idea that p53 in the revertants has maintained wild-type properties. Differential DNA binding by
p53 between HeLa and revertants further supports the idea that p53 has been functionally
activated in the revertants.
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Graph 1: 5*106 cells were transiently transfected with 1Optg of CAT-reporter constructs pG13-
CAT or pmGl5-CAT. pGl3-CAT and pmGl5-CAT correspondingly carry the CAT gene under
the control of polyoma late promoter preceded by 13 repeats of wild-type p53 consensus binding
sites and 15 repeats of mutated p53 consensus binding sites. This experiment showed the
manifestation of wild-type-p53 specific transactivation in the revertants as opposed to HeLa.
Treatment with Actinomycin D and y-irradiation which induce p53 protein also induce p53-
specific transactivation.
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Figure 2.4: Differential expression of gadd45 and waf-1 in HeLa and revertants.
Northern blot on 15jig of total mRNA from HeLa, HA and HF exposed to 5 Gray (t for treated)
or 0 Gray (u for untreated) of y-irradiation. Top panel: Gadd 45 is expressed in the untreated
revertants but is not detectable in treated or untreated Hela cells. Middle panel: Waf-1 is induced
by y-irradiation in the revertants but not in HeLa. Bottom panel: Ethidium bromide staining of the
Northern blot to ensure equal loading and transfer.
103
T'able 2.11I: Retroviral transfer and expression of wild-type p53 suppresses Hela transformation
T'able 2.111: Exponentially growing HeLa carrying the wild-type p53 or vector LXSN alone were
removed from dishes by trypsinization and diluted with MEMN + 10% FBS. Aliquots containing
104 cells and 103 cells were removed and seeded into molten Agar in 30mm dishes. Results
shown here represent averages of two independent experiments carried out in duplicates showing
the difference in anchorage independent growth per 103 cells seeded between HeLa expressing
p53 and the corresponding control Hela LXSN cells. Also shown are the differences per 104 cells
seeded between revertants expressing mutantl75 (His to Arg) p53 and the corresponding control
cells with LXSN.
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Cell Line Cloning
efficiency (%)
HeLa + LXSN 40
HeLa + wt p53 < 0.4
HA + LXSN < 3
HA +mut 175 < 2
HF + LXSN < 0.1
HF + mut 175 <0.1
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Figure 2.5: Differential p53 degradation in HeLa and revertant lysates.
(a) Autoradiogram of p53 degradation reactions with partially purified E6 activity from HeLa and
revertants. Degradation reactions were carried out in ubiquitination reaction buffer with 6Ltg
ubiquitin and 2mM ATP or 2mM ATP-y-S. Reactions were ran for a time course of 3hrs at 300C.
'They were then stopped with Laemmli bufferand half of each reaction was loaded on a 10% SDS-
PAGE gel. Gels were dried out and exposed on a phosphorimager screen overnight.
(b) Western blot of of p53 degradation reactions with total cell lysates. Gels of reactions carried
out with non-radiolabeled p53, were subjected to Western blotting with antibody DO-1.
Both (a) and (b) H= HeLa, A = HA, F = HF. 0 time pont contained no extract and was kept on ice
for 3hours. Samples containing ATP-,y-S as indicated. RRL = Reticulocyte Lysate Extract only
included in the degradation reaction. * = band A (see Results section).
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Figure 2.6: E6 binding to p53 is interrupted in both revertants
Western blot of E6 following a immunoaffinity purification of p53 and associated proteins. A
15% mini Laemmli SDS-PA gel was run for 2hrs at 80V.
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Discussion
In order to study cervical cell transformation we have employed an in vitro cell culture
system comprising of the cervical carcinoma cell line HeLa and two non-tumorigenic variants
(revertants), HA and HF. Such systems have been used succesfully to identify the ras tumor
suppressor gene krev (Noda et al., 1991) and transformation effector genes (Boylan et al., 1991;
Kho et al., 1991), whose products comprise and/or regulate the biochemical pathways of cellular
transformation. The isolation and initial characterization of our two HeLa revertants, HA and HF
are described elsewhere (Athanassiou, M. et al, 1996). Briefly,the revertant cell lines have been
selected for morphology and for loss of prolonged rhodamine retention by fluorescence-activated
cell sorting; they have lost the ability to grow in suspension culture or in soft agar medium, as
well as the ability to form tumors in nude mice. The HeLa cells harbor approximately 10-20
copies of the high risk HPV-18 DNA per genome equivalent (Lazo et al., 1987; Lazo et al., 1989;
Schwarza et al., 1985). These sequences are preserved in the revertants and all three cell lines
express the E7 and E6 viral oncogenes. Retroviral trasnduction of E6 and E7 or hybrid E7/E7
mRNA in the revertants had no effect in the revertant phenotype. Since maintained function of
the revertants has been shown to be necessary for the mmaintenance of the transformed
phenotype, one possible explanation for the latter result would be that the E6 and/or E7 functional
pathways have been interrupted in the revertants. The transforming functions of E6 and E7
culminate in their respective binding of the p53 and Rb tumor suppressor genes. To assess E6 and
E7 function we have examined the state of the Rb and p53 in Hela revertants. In both revertants
and particularly -IF, we found Rb-E2FI interactions which were non-detectable in HeLa. But the
most striking similarity between the two revertants was an increase in p53 protein level with
respect to HeLa.
The p53 in our parental HeLa clone has been reported to be wild-type (Scheffner et al.,
199). Mutation of the p53 gene could have increased p53 protein half-life in the revertants and
could have resulted in the observed increase in p53 protein levels in the revertants. HA and HF,
however, are independent revertants as shown by their distinct growth and morphologies, by a
difference in their hybridization pattern with a human VNTR probe as well as by the differential
expression of a number of genes tested. Since there are about one million genes within the human
genome, the probability of mutation within one given gene is 10-6. Thus the probability of
mutation within the p53 in two independent revertants is about 10-12 . Moreover, p53 mutation
would be likely to negate the reversion process thus its occurence in both independent revertants
would be counterintuitive. Nevertheless we have tested for p53 mutation in both revertants as
well as the parental HeLa cells. Sequencing in both orientations of the region corresponding to
exons 4-11 of the p53 gene from twelve cDNA clones of each cell line , showed no mutation in
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any of the cell lines. p53 mutations in human cancers occur within exons 5-8 which were included
in our sequenced regions. Serine 315, phosphorylation of which is necessary for ubiquitin-
dependent degradation of p53 (Lin and Desiderio, 1993), was also not mutated in revertants and
HeLa.
We have thus hypothesized that the increased p53 protein levels in the HeLa revertants
could have resulted in functional p53 activation which would in turn have contributed to or even
caused the revertant phenotype. We have therefore tested whether endogenous p53 in the
revertants has acquired transcription function properties not manifested in Hela and specific to
the wild-type p53 protein. We have used retroviral transduction to establish that p53 function is
sufficient to suppress the transformed phenotype of the HeLa cell and we have finally attempted
to assess the extent of the contribution of the endogenous p53 to the revertant phenotype.
Exposure to y-irradiation or Actinomycin D has been shown to induce p53 protein levels
and to y-irradiation has been shown to cause specific induction of the gadd5 and waf-1 genes in
cells expressing wild-type p53, but not in cells with mutant p53 (Kastan et al., 1991, 1992 and
1993; El Deiry et al., 1993). We found that in both revertants but not in HeLaEndogenous p53 is
inducible by treatment with Actinomycin D and y-irradiation and active as a constitutive and
inducible transcription factor in both revertants but not in HeLa. Exposure to ActinomycinD and
'y-irradiation follows different kinetics but induces p53 protein levels to more that ten times that of
HeLa at the time point of maximal induction. The kinetic ratesof p53 induction are also more
than ten fold higher in the revertants than in HeLa. Notably the HA cell line shows the greatest
response to both treatments.
Endogenous transactivational activity in the revertants was able to transactivate the CAT
reporter construct pG13 CAT in a p53 dependent manner (Kern et al., 1993). p53 transactivating
activity in untreated HF and HA was respectively 30-fold and 20-fold higher than in HeLa. Thus
the difference in p53 activity are significantly greater than the difference in the levels of the p53
protein. Transient treatment with Actinomycin D and exposure to y-irradiation did not
significantly increase p53 activity in the HF cell line. Both tretments increased activity in HA by
over two-fold and up to 50-fold with respect to HeLa. The observed increase in p53 function after
y-irradiation or ActD (2-fold) was not as dramatic as the observed (10-fold) increase in protein
levels but this result is in agreement with a previous report by Zhan et al., (1993). It is possible
that due to the multiplicity of the p53 binding sites the pG13 CAT promoter is nearly maximaly
transactivated in untreated cells. Alternatively the posttranscriptional modification of the p53
protein that causes its induction may also alter its transactivational effects on the pG13 CAT
promoter. Nevertheless these results reinforce other lines of evidence that suggest p53 is better
induced in the HA than in the HF revertant.
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Gel Shift assays detected p53 binding on a single repeat of the p53 consensus sequence
and on the intronic p53 binding sequence of the gadd45 gene upon induction with actinomycin D
and y-irradiation in revertant and positive control but not in HeLa nuclear lysates.
The downstream effectors of the transcriptionally active p53, namely the waf-1 and
gadd-45 genes, are expressed in the revertants but not in HeLa. waf-l mRNA is undetectable in
untreated cells and induced upon irradiation of the revertants. waf-1 induction is absolutely
dependent upon wild-type p53 function thus this result offers good evidence for the functional
activation of the revertant p53. Expression of the gadd-45 mRNA is constitutive in the revertants,
and irradiation has a slightly suppressive effect. p53 involvement in gadd45 induction is specific
to y-irradiation and not other treatments (Zhan, 1993 and Kastan 1992), however,
the fold difference in HeLa and revertant gadd45 mRNA is equal to the maximal induction
reported for any cell line (RKO cells; Kastan et a., 1992). Thus, gadd45 levels may already be
maximally induced in revertants with respect to HeLa gadd45 mRNA levels. p5 3 specific
binding of the gadd45 binding site is detectable in the revertants but not in HeLa and inducible by
y-irradiation and if constitutive gadd45 expression were under p53 control the gadd45 result ould
be in agreement with the CAT assay data I is also possible that the y-irradiation-dependent
pathway of gadd45 induction may have been interrupted by mutation of some factor other than
p53 in the parental HeLa cell.
Taken together results from CAT assays, DNA binding and endogenous gene expression
have established that endogenous revertant p53 protein manifests the transcriptional properteis of
the wild-type p53 and is thus shown to be functionally activated with respect to HeLa p53. A
strong correlation between the transcriptional activity of p53 and the reversion from cervical
carcinoma has thus been established and offers valuable evidence that the transcriptional
properties of the wild-type p53 contribute to its role in growth regulation.
In order to establish that wild-type p53 function is sufficient to suppress HeLa
transformaation we have used retroviarl transduction to ectopically express wild-type p53 in the
revertants. We saw a 100-fold reduction of colony growth in soft agar in the wild-type p53
expressing pull of infected HeLa cells. Similar results have been obtained for tumor cell lines of
other origin but not for cervical carcinoma cells. It is actually surprising that the exogenous p53
could have such an effect given the presence of the E6 protein in the Hela cells.
In order to directly assess the extent of the conribution of p53 to the revertant phenotype
we have attempted to counteract wild-type p53 function in the revertants by retroviral integration
and ectopic expression of a dominant negative mutant p53. Retroviral transduction of the 175 His
to Arg mutant did not result to increased clonigenicity of the revertants in soft agar and we are
planning to use antisense mRNA to lower the expression of endogenous revertant p53 and
definitively prove its contribution to the revertant phenotype. In retrospect, the failure of
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dominant negative mutant was expected if endogenous p53 in the revertants had gained wild-
type p53 function, since all lines of evidence suggests that in the in vivo context wild-type p53
has a dominant effect over the mutants biochemically defined as dominant (see Results section).
Thus results from the retroviral transfer and expression of the 175 mutant in the revertants taken
together with the manifestation of endogenous p53 function in the revertants are consistent with a
dominance of wild-type p53 function in vivo in the context of the revertant cells.
We have been interested in identifying the cause of p53 activation in the HeLa revertants.
One possible cause for p53 activation would be loss of E6 function. Functional inactivation of E6
in either revertant would ultimately lead to lack/reduction of p53 ubiquitination and degradation.
It is also conceivable that interruption of p53 ubiquitination or degradation could occur
independent of E6 function and result in p53 activation in the revertants. We have thus used in
vitro experiments to address whether differential reduction of ubiquitin-dependent degradation in
the revertants could account for p53 stabilization. p53 protein was made by in vitro translation in
reticulocyte lysate extracts. incubated with HeLa or revertant cell lysates in the presence of
ubiquitin and ATP or ATP-y-S. Addition of ATP-y-S, prevents degradation of high molecular
weight ubiquitinated intermediates by the proteasome and allowed us to differentiate ubiquitin
dependent degradation from general proteolysis. When we used a partialy purified fraction of
basic proteins that contains concentrated HeLa and revertant E6 protein in the degradation
reaction mixture we saw that degradation of the in vitro translated p53 was faster in the HeLa
samples. This result suggested that differential degradation of p53 may be the cause of p53
accumulation in both revertants and the result of loss of E6 function and was in agreement with
our retroviral transduction data. We have also observed active inhibition of p53 degradation in the
HF cell lysate. Future experiments will dissect in greater detail the ubiquitination-degradation
pathways in HeLa and revertants and will aim at identifying the cause of differential p53
degradation in these three cell lines.
Given the: evidence suggesting loss of E6 function we have investigated whether E6-p53
interaction was interrupted in the revertants. This was a technically challenging experiment to
carry out, given the relatively low abundance of E6 protein. Immunoaffinity purification of p53
complexes from 20mg of HeLa and revertant cell lysates and subsequent immunoblotting with an
anti-E6 antibody showed that E6-p53 interaction has been disrupted in the revertant cells. This
result definitively identified loss of E6 function as the cause of p53 activation in the revertant
cells. Since the loss of E6 function is upstream of E6 p53 binding change within an E6 regulating
pathway is the most likely cause of reversion in both HA and HF and we shall actively investigate
for differences in the activities of putative E6 regulators.
In an earlier report we have shown that binding of p53 to p34cdc2 occurs in HeLa and
HA cells but not in HF cells. p53 is phosphorylated in vivo and in vitro by cdc2p34 (Milner et al.
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1990; Sturzbecher et al., 1990; Bischoff et al., 1990) on Serine 315. The predominant NLS is
located adjacent to serine 315 (312 for mouse and rat p53). Thus phosphorylation of this serine
residue could influence p53 subcellular localization and biological activity in a cell cycle
dependent manner. Most importantly, however, Lin and Desiderio have shown that lack of
phosphorylation ,on Serine 315 inhibits the ubiquitin dependent degradation of p53. Thus the
observed inhibition of p53 degradation in the HF revertant could be explained by the lack of its
interaction with p34cdc2. Since E6 has been reported to bind an unidentified 35 kDa protein it
would be interesting to investigate whether E6 also binds p34cdcd2 and whether phosphorylation
of p53 on Ser 315 may be required for E6-p53 binding as suggested by our data for the HF cell
line. Interestingly, p34cdc2 is also bound by theSV40 Large T Antigen () which like E6 binds and
inactivates p53. SV40 binding to E6 leads to increased p53 half-life, and increased p53
phosphorylation (). Cyclin A-cdk2 complexes by SV40 and E1A are able to phosphorylate p107
which is also bound by these oncogenes in the same cell cycle dependent manner than they would
if they were not bound by the viral oncogenes. It is thus possible that when bound to SV40 Large
T p53 may be iphosphorylated by p34cdc2 and this interaction may be important for p53
inactivation by SV40 Large T. The lack of p34cdc2 -p53 interaction in the HF cell line may thus
explain why SV40 Large T fails to retransform HF. In contrast, SV40 Large T can retransform
HA and p34cdc:2 -p53 interaction is preserved in the HA revertant while E6-dependent
degradation of p53 is blocked. Thus p34 cdc2 may be a common regulator of two biochemically
distinct pathways through which SV40 Large T and E6, each exert their inactivating effects on
p53. In the HF revertant inactivation of p34 cdc2 may disrupt the function of both viral oncogenes
while in the HA revertant SV40 Large T can still exert its inactivating effect on p53. Future
experiments will attempt to verify these hypotheses.
In summary, completed work establishes that p53 which can suppress the tumorigenicity
of the HeLa cell, is functionally activated in the revertants. Loss of E6 function and of ubiquitin
dependent degradation have been identified as the cause for functional p53 activation and a
testable hypothesis has been formulated about the involvement of p34cdc2 in the functional
pathway of the E6 viral oncogene. These results point to the value of this system for the study of
cervical cell transformation and show great promise for advancing our understanding of p53 and
viral oncogene function.
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SIGNIFICANCE AND FUTURE EXPERIMENTS
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This Research Thesis describes the initial characterization of non-transformed revertants
isolated from HeLa cells on the basis of prolonged rhodamine 123. Initial phenotypic
characterization of the revertants demonstrated that these cells lost most of the in vitro properties
associated with transformed cells, including a transformed morphology, clonigenicity in semi-
solid medium, and growth in suspension culture (Boylan et al, 1996). Stanbridge and co-workers
have previously carried out somatic cell hybridization experiments using HeLa cells and primary
human fibroblasts and showed that the tumorigenicity of HeLa cells is suppressible (). They have
futher demonstrated that a tumor suppressor gene harbored on the short arm of human
chromosome 11, is able to suppress the tumorigenicity of HeLa cells (Maniatis et al., 1982;
Srivatsan et al, 1986 ; Stanbridge et al., 1986). However, all of the non-tumorigenic cell hybrids
generated from the fusion of HeLa cells and normal human fibroblasts invariably maintained the
in vitro characteristics of the transformed parental Hela. Thus, loss of the tumor suppressor gene
on chromosome 11 :is likely to be associated with tumor progression rather than initiation of
carcinogenesis. In contrast, the events that led to reversion in our system may have affected early
pathways of transformation, such as E6 and E7 functional pathways. In rodent transformed cell /
revertant cell systems reversion is often the cause of inactivatng mutation within the transforming
oncogene (). Our knowledge of the involvement of E6 and E7 in cervical transformation makes
each of these genes the analogue of the transforming oncogene in the rodent systems. It was
therefore necessary to examine the possibility of functional inactivation of each of the two
oncogenes.
Continued expression of the E6/E7 genes -which has been found necessary for the
maintenance of the transformed phenotype of the HeLa cell (Schwarz et al., 1985; Schneider-
Gadicke et al., 1986; Schneider-Gadicke et al., 1987; Bosch et al., 1990; Bosch et al., 1991)- was
verified in the revertants. Retroviral transduction of HPV-16 E6, E7 or a combination of the two
had no effect on the revertant phenotype. On the other hand, cell fusion experiments between
HeLa and revertants raised the possibility that a tumor suppressor gene may have been activated
during the reversion process. Since the transforming functions of the "high risk" HPV E6 and E7
are thought to result from their respective binding and inactivation of the p53 and Rb tumor
suppressor proteins (Dyson et al., 1989; Munger et al., 1989; Munger et al., 1989; Werness et al.,
11990) functional inactivation of the E6 and/or E7 could be manifested as activation of either Rb
or p53 tumor suppressors. Such activation could be caused by a change in a regulator of either
tumor suppressor or of the relevant HPV oncogene protein and a subsequent interruption of the
association between the viral oncoprotein and cellular tumor suppressor. We have thus examined
the state of the p53 and Rb tumor suppressor genes in HeLa and revertant cells.
We found increased steady state levels of wild-type p53 in both revertants despite the
presence of the E6 protein. Detectable Rb-E2FI binding in the revertants suggested functional Rb
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activation. In addition, qualitative changes in protein-protein interactions in both the Rb and p53
pathways were observed in the HF revertant. To this point our data had established that reversion
of transformation was the result of functional inactivation of the E6 and E7 pathways in the
revertants. Increase of the levels of p53 was the most consistent and striking difference between
HeLa and the revertants and the remainder of the research presented in this report focused on the
study of the p53 gene product in our system. We have thus shown that wild-type p53 can suppress
the HeLa phenotype. We have further succeeded in establishing that revertant p53 is wild-type
and that wild-type-p53-specific functions are manifested in the revertants but not in HeLa.
Finally, we have shown that decreased p53 proteolysis is the probable cause of increased p5 3
levels in the revertants with respect to HeLa. Loss of E6 function and of ubiquitin dependent
degradation have been identified as the cause for functional p53 activation and a testable
hypothesis has been formulated about the involvement of p34cdc2 in the functional pathway of
the E6 viral oncogene. Although the extent of p53 contribution to the revertant phenotype remains
to be: assessed, the research presented here emphasizes the central role of the HPV and p53
pathways in cervical transformation and offers in vivo evidence for the link between the
transcriptional activity of p53 and the control of cell growth. These results point to the value of
this system for the study of cervical cell transformation and illustrate its great promise for
advancing our understanding of p53 and viral oncogene function. Most importantly, this work
:suggests that interference with the HPV functional pathway or activation of the p53 pathway may
'help control cervical carcinoma cell growth and may be a reasonable approach to the development
of new therapeutic strategies. The use of transformant/revertant human carcinoma cell systems
isolated for loss of prolonged rhodamine retention is thus validated as a more general approach to
the study of human carcinoma cell transformation.
The failure of dominant negative p53 mutant to retransform the revertants is consistent
with activation of p53 in these cells, since all lines of evidence suggests that in the in vivo context
wild-type p53 has a dominant effect over the dominant negative mutants. Although other lines of
experimentation strongly corroborate this interpretation, it would be desirable to test the extent of
p53 contribution to the revertant phenotype in each revertant. We are thus planning to use
antisense mRNA to lower the expression of endogenous revertant p53 and definitively prove its
contribution to the revertant phenotype.
p53 activation is attributed to loss of E6 function upstream of E6-p53 binding. Change
within an E6 regulating pathway is the most likely cause of reversion in both HA and HF. We
shall thus investigate differences in the activities of putative E6 regulators.
Decreased binding of p53 to p34cdc2 in HF cells may have been caused by mutation in
p34cdc2 itself or by its inactivation by a molecule such as the cyclin activating kinase (CAK; for
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review see Solomon, 1995). Either inactivation of p34cdc2 or functional activation of CAK
would have profound effects in the cell cycle. It thus becomes imperative to study the
significance of the interaction of p34cdc2 and p53 as well as the cause for its absence in the HF
cell. We shall therefore check whether changes in p34cdc2 activity are manifested in the
revertants by immunoprecipitation of p34cdc2 followed by kinase activity assay in
immunoprecipitated complexes. We shall use functional assays such as those performed for viral
oncogenes and p53 to test whether mutation of p34cdc2 or differential CAK activity can account
for differences in p34cdc2 function. Furthermore, in order to investigate the significance of
p34cdc2-p53 interaction we shall examine its cell cycle and DNA damage dependence and the
codependence of p34cdc2 activity and p53 phosphorylation. The performance of these
experiments in HeLa revertants and control primary human keratinocytes and Saos-2 cells will
allow us to establish a cause-and-effect relationship in the p53-p34cdc2 association.
Lin and Desiderio have shown that lack of phosphorylation on Serine 315, the p34cdc2
substrate, inhibits the ubiquitin dependent degradation of p53. Thus the observed inhibition of
p53 degradation in the HF revertant could be explained by the lack of its interaction with
p34cdc2. Since E6 has been reported to bind an unidentified 35 kDa protein it would be
interesting to investigate whether E6 also binds p34cdcd2 and whether phosphorylation of p53 on
Ser 315 may be required for E6-p53 binding as suggested by our data for the HF cell line.
Interestingly, p34cdc2 is also bound by theSV40 Large T Antigen () which like E6 binds and
inactivates p53. SV40 binding to E6 leads to increased p53 half-life, and increased p53
phosphorylation. Cyclin A-cdk2 complexes by SV40 and EIA are able to phosphorylate p107
which is also bound by these oncogenes in the same cell cycle dependent manner than they would
if they were not bound by the viral oncogenes. It is thus possible that when bound to SV40 Large
T p53 may be phosphorylated by p34cdc2 and this interaction may be important for p53
inactivation by SV40 Large T. The lack of p34cdc2 -p53 interaction in the HF cell line may thus
explain why SV40 Large T fails to retransform HF. In contrast, SV40 Large T can retransform
HA and p34cdc2 -p53 interaction is preserved in the HA revertant while E6-dependent
degradation of p53 is blocked. Thus p34 cdc2 may be a common regulator of two biochemically
distinct pathways through which SV40 Large T and E6, each exert their inactivating effects on
p53. In the HF revertant inactivation of p34 cdc2 may disrupt the function of both viral oncogenes
while in the HA revertant SV40 Large T an still exert its inactivating effect on p53. Future
experiments will attempt to verify these hypotheses.
Finally, we shall investigate the role of p53 in cell death or growth arrest upon induction
with Actinomycin D and y-irradiation in the context of the revertant cells. We shall compare
revertants with Hela cells expressing wild-type p53 in order to assess the contribution of p53 to
these response in the revertants. These cell cycle studies will provide further evidence for the
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contribution of the p53 in the revertant phenotype, but they may also point out differences in the
functional pathways involved in reversion and p53 activation of each cell line.
Metabolic labeling and immunoprecipitation of Rb protein from HeLa and revertants
suggested that their may be differences in the Rb phosphorylation potential of revertants and are
currently investigating this hypothesis. Rb changes in phosphorylation may account for the co-
immunoprecipitation of Rb with E2FI from revertant cell lystates that suggests Rb activation.
Although Rb-E2FI complex formation suggests Rb activation in the revertants a more
definitive proof of gain of Rb function would be given by a direct indication of a suppressive
effect of Rb on E2FI function as measured in transcription and DNA binding assays in the
revertants. The extent/dose of functional Rb activation may be important to Rb contribuion in the
reversion process as may be the interplay between Rb and p53 gain of function in the revertants.
We are currently investigating whether complex formation between Rb and E2F-1 could account
for differential E2F-1 activity in the revertants and what changes in Rb or E2F regulation can
account for the restoration of complex formation in HF. We are also testing the hypothesis that
gain of function of Rb through this complex may have contributed to the reversion (Hiebert et al.,
1993 ). E2F1-Rb association is transient in the cell cycle and dependent on Rb phosphorylation
by cell cycle regulatory complexes (Schwarz et al., 1993 ; Shirodkar et al., 1992; Hiebert et al,
1993; Nevinset al., 1992) An investigation of the Rb phosphorylation mechanisms in the
revertants may identify the reversion event among the most basic mechanisms of cell cycle and
growth control.
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